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During	 the	 last	 20	 years,	 the	 cutaneous	 administration	 of	 active	 principles	 has	 been	
taking	a	key	role	not	only	for	the	possibility	to	achieve	high	skin	drug	concentrations	for	
the	 treatment	 of	 local	 pathologies,	 but	 also	 for	 reaching	 therapeutic	 plasmatic	
concentrations	 for	 systemic	 administration.	 In	 the	 field	 of	 cutaneous	 delivery,	 film-
forming	 systems	 and	 transdermal	 patches	 are	 the	 most	 widely	 used	 dosage	 forms	
because	they	are	able	to	firmly	adhere	to	the	skin	and	release	the	active	substance(s)	
for	the	entire	treatment	period.	Despite	many	products	are	currently	available	on	the	
market,	some	critical	aspects,	such	as	adhesive	and	mechanical	properties,	as	well	as	
rheological	behavior	of	 these	pharmaceutical	dosage	 forms,	 are	 still	 scarcely	 studied	
since	most	of	the	research	is	overlooking	their	importance	dealing	with	drug	delivery,	
pharmacokinetic	 and	 safety	 evaluation.	 Hence,	 there	 is	 the	 need	 to	 study	 the	most	
relevant	 issues	 involved	 in	 the	design	of	 both	 film-forming	 systems	and	 transdermal	
patches	 and	 clarify	 the	 possible	 relationships	 between	 rheological	 pattern,	 adhesive	
properties	and	in	vitro	biopharmaceutical	performances.	This	kind	of	relationship	could	
provide	 useful	 information	 to	 design	 and	 optimize	 both	 film-forming	 systems	 and	
transdermal	patches.		
	
This	doctoral	 thesis	aimed	to	evaluate	the	effect	of	 the	 formulation	compositions	on	
rheological,	 adhesive	 and	 mechanical	 properties	 as	 well	 as	 on	 the	 in	 vitro	
biopharmaceutical	 performances	 of	 different	 polymeric	matrices,	 in	 order	 to	 design	
film-forming	systems	and	transdermal	patches.	In	particular,	the	experimental	work	was	
focused	on:	
(1) the	design	of	 film-forming	systems	based	on	an	ammonium	methacrylate	copolymer	
(Eudragitâ	RL)	solubilized	in	a	mixture	of	solvents	in	different	ratios	and	plasticized	by	
different	amounts	of	plasticizer;	the	effects	of	solvent	systems	as	well	as	the	addition	of	
the	plasticizer	were	evaluated	on	drying	time,	outward	stickiness,	mechanical	properties	
and	in	vitro	biopharmaceutical	performances;	
(2) the	 design	 of	 transdermal	 patches	 based	 on	 a	 differently	 plasticized	 ammonium	
methacrylate	copolymer	(Eudragitâ	RL)	and	the	evaluation	of	their	rheological	and	tack	
properties,	primarily	to	better	understand	their	debonding	mechanisms	and	adhesive	
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characteristics;	 moreover,	 the	 main	 technological	 and	 in	 vitro	 biopharmaceutical	
properties	were	tested;	
(3) the	 design	 of	 transdermal	 patches	 based	 on	 a	 styrenic	 copolymer	 (styrene-block-
(ethylene-co-butylene)-block-styrene,	 SEBS);	 the	 effects	 of	 SEBS	 and	 tackifiers	
molecular	 weights	 on	 the	 rheological	 and	 adhesive	 properties	 were	 investigated.	 In	
particular,	the	debonding	behavior	under	different	operative	conditions	was	evaluated	
and	 the	 technological	 as	well	 as	 the	 in	 vitro	 biopharmaceutical	 performances	 of	 the	
formulated	patches	were	studied.	
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The	 relevance	 of	 transdermal	 dosage	 forms	 is	 due	 to	 the	 possibility	 to	 obtain	 a	
prolonged	drug	 release	over	a	period	of	 time	up	 to	24	hours.	Nowadays,	among	 the	
several	transdermal	delivery	systems	actually	developed,	film-forming	systems	(FFS)	and	
transdermal	patches	(TP)	are	the	most	widely	used	because	of	their	abilities	to	firmly	
adhere	to	the	skin	and	to	release	the	active	substance(s)	for	the	entire	treatment	period,	
thus	assuring	a	prolonged	and	adequate	drug	permeation	through	the	skin.		
FFS	are	innovative	drug	delivery	systems	intended	to	be	applied	onto	the	skin	in	order	
to	achieve	a	systemic	effect	[1].	They	are	composed	by	a	vehicle	(a	volatile	solvent	or	a	
mixture	of	solvents),	in	which	the	polymer	and	the	active	substance(s)	can	be	dissolved	
or	dispersed	[2].	After	the	application	to	the	skin,	the	volatile	vehicle	should	evaporate	
resulting	 ultimately	 in	 an	 in	 situ	 formation	 of	 a	 polymeric	 film.	 Since	 this	 allows	 a	
significant	 quantitative	 change	 in	 the	 composition	of	 the	 film,	 usually	 a	 plasticizer	 is	
added	to	overcome	the	brittleness	of	the	final	film	[1].	
TP	 are	 flexible	 and	 self-adhesive	 pharmaceutical	 preparations	 of	 varying	 sizes,	
containing	one	or	more	active	substances	and	they	are	intended	to	be	applied	to	the	
unbroken	skin	in	order	to	deliver	the	active	substance(s)	to	the	systemic	circulation	after	
passing	through	the	skin	barrier	[3].	Nowadays,	the	same	systems	are	used	to	obtain	
either	local	or	regional	effects.	According	to	their	design,	patches	can	be	divided	into	
matrix	 and	 reservoir	 types.	 Among	 the	 matrix	 platforms,	 drug-in-adhesive	 systems	
consist	 of	 an	 adaptable	 backing	 layer,	 an	 adhesive	 matrix,	 in	 which	 the	 active	
substance(s)	 is	 dissolved	or	dispersed,	 and	a	 removable	 release	 liner.	 These	 systems	
allow	to	improve	patient’s	compliance	because	they	are	thin,	flexible,	comfortable	and	
conformable	 [4].	 Furthermore,	 from	 a	 formulative	 point	 of	 view,	 they	 are	 easy	 and	
cheap	to	produce	[5].		
The	systemic	treatment	by	delivering	a	drug	through	the	skin	by	using	both	FFS	and	TP	
is	gaining	an	increase	interest	due	to	their	several	advantages.	In	particular,	transdermal	
delivery	provides	convenient	and	pain-free	self-administration	for	patients;	it	avoids	the	
hepatic	 first-pass	metabolic	 effects	 associated	with	 the	oral	 administration	of	 drugs.	
Since	it	offers	controlled	release	of	the	drug,	it	also	enables	a	steady	blood	level	profile,	
resulting	in	reduced	systemic	side	effects	and,	sometimes,	improved	efficacy	over	other	
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dosage	forms	[6].	All	these	advantages	lead	to	enhance	patient	compliance,	especially	
when	long-term	treatment	is	necessary.		
In	order	to	design	suitable	FFS	or	TP	some	critical	issues	must	be	taken	into	account.	In	
particular,	drug	absorption	process	depends	on	the	drug	partition	between	the	dosage	
form	and	the	skin	and	subsequently	on	the	permeation	of	the	active	ingredient	through	
the	 stratum	 corneum.	 Therefore,	 to	 assure	 a	 prolonged	 permeation	 of	 the	 active	
substance(s)	through	the	skin,	a	whole	contact	between	the	dosage	form	and	the	intact	
delivery	surface	for	the	entire	treatment	period	is	critical	[7].	A	strongly	adhesion	of	the	
dosage	 form	 to	 the	 skin	 determines	 drug	 delivery,	 therapeutic	 effects	 and	 patient	
compliance	[8].	
To	 satisfy	 this	 requirement	 the	 use	 of	 bioadhesive	 materials,	 that	 are	 defined	 as	
materials	able	to	adhere	to	a	biological	substrate	and	being	retained	on	such	substrate	
for	an	extended	period	by	interfacial	forces	[9],	is	mandatory.		
In	particular,	focusing	on	FFS,	the	main	features	which	should	be	considered	during	a	
formulative	study	are	the	time	required	for	the	in	situ	film	formation	(drying	time),	the	
cosmetic	attributes	of	the	formed	film	and,	mostly,	its	mechanical	properties.		
With	respect	to	the	conventional	topical	dosage	forms,	a	good	and	more	patient-friendly	
formulation	would	 be	 fast	 drying	 (i.e.	 in	 vivo	 a	 drying	 time	 lower	 than	 5	minutes	 is	
mandatory)	 and	 the	 minimum	 film-forming	 temperature	 should	 be	 below	 the	 skin	
surface	 temperature.	 The	 formed	 film	 should	be	 cosmetically	 acceptable	 (i.e.	 almost	
invisible)	and	non-sticky	to	avoid	adhesion	to	patient’s	clothes.	Moreover,	suitable	films	
intended	for	applications	as	transdermal	drug	delivery	systems	must	be	not	only	flexible	
enough	to	follow	the	body	movements	without	breaking,	but	also	sufficiently	persistent	
to	prevent	abrasion	of	the	film	caused	by	cloths	frictions	[10].		
In	order	to	satisfy	the	requirements	of	flexibility	and	elongation	necessary	to	assure	a	
proper	 skin/dosage	 form	 contact,	 the	 in	 situ	 formed	 film	 should	 present	 a	 glass	
transition	 temperature	 below	 than	 the	 skin	 surface	 temperature	 (32	 °C).	 Usually,	 a	
plasticizer	 is	 added	 to	 reduce	 the	 polymer	 glass	 transition	 temperature	 and	 the	
brittleness	of	the	final	film.	In	the	formulation	of	FFS	the	selection	of	the	proper	amount	
of	plasticizer	is	crucial	since	a	certain	reduction	of	the	glass	transition	temperature	(Tg)	
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is	mandatory	to	obtain	suitable	mechanical	properties,	but,	on	the	other	hand,	an	excess	
of	plasticizer	could	cause	the	formation	of	a	sticky	film	on	the	skin.	
Regarding	 TP,	 the	 adhesion	 is	 guaranteed	 by	 the	 so-called	 “pressure-sensitive	
adhesives”	(PSAs),	that	are	the	main	components	of	a	drug-in-adhesive	patch.	They	are	
self-adhesive	 polymeric	 materials	 that	 display	 an	 instantaneous	 adhesion	 on	 most	
surfaces,	such	as	the	skin,	by	applying	a	light	pressure;	moreover,	they	can	ideally	be	
detached	without	any	residue	[11].		
Tack,	shear	and	peel	adhesion	represent	the	main	features	of	patch	adhesion.	Tack	gives	
rise	 to	 the	 initial	adhesion	of	 the	patch	to	 the	skin	under	 light	pressure	and	on	brief	
contact.	Since	patients	usually	apply	the	patch	slowly	and	with	accuracy,	low	tack	values	
are	desired.	Shear	adhesion	represents	the	resistance	of	the	PSA	to	flow	and	provides	
an	 indication	of	 its	cohesiveness.	A	patch	should	remain	attached	to	the	skin	 for	 the	
entire	treatment	period	and	it	should	resist	to	the	stresses	due	to	body	movements	and	
cloths	frictions;	hence,	high	shear	adhesion	values	(about	hours)	are	required.	Lastly,	
peel	adhesion	refers	to	the	force	required	to	remove	the	patch	from	the	skin	at	the	end	
of	the	treatment	period.	In	this	latter	case,	low	values	are	related	to	the	absence	of	both	
pains	and	adhesive	residues	during	the	peeling	process	[12].		
Given	these	preliminary	considerations,	a	patch	should	be	sticky	and	exhibit	an	optimal	
balance	between	adhesiveness	and	cohesiveness.		
To	obtain	a	sticky	material	the	knowledge	of	the	polymer	Tg	is	crucial	since	it	influences	
the	modulus	of	elasticity	of	the	polymer	itself.	An	increase	in	polymer	Tg	improves	the	
hardness	and	stiffness	of	the	material	itself	[13].	Polymer	with	high	Tg	value	allows	to	
produce	a	very	strong,	but	brittle	matrix,	while	low	Tg	value	permits	to	obtain	flexible	
matrixes.	Furthermore,	Zosel	A.	demonstrated	that	to	make	an	uncross-linked	or	slightly	
cross-linked	polymer	sticky	and	adherent	to	almost	any	surface,	its	Tg	should	be	25-45	
°C	lower	than	the	application	temperature	[14].	Since	the	skin	surface	temperature	is	
about	32	°C,	it	is	reasonable	to	suppose	that	materials	with	a	Tg	lower	than	-10	°C	are	
sticky	when	applied	onto	the	skin	and	they	can	be	used	to	design	transdermal	patches	
able	 to	 adhere	 to	 skin.	 Usually,	 the	 addition	 of	 compatible	 excipients,	 such	 as	
plasticizers,	 that	 remain	 homogeneously	 dispersed	 or	 dissolved	 into	 the	 final	matrix	
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after	solvent	evaporation,	is	necessary	to	reduce	the	polymer	Tg	and	to	produce	certain	
desirable	effects	on	the	physical	properties	of	the	final	polymeric	matrix:	this	changing	
transforms	the	polymer	from	a	glassy	and	rigid	material	to	a	viscous	one,	making	it	softer	
and	more	 flexible	 [15].	 Plasticizers	 are	 low-molecular	 weight	molecules	 that	 reduce	
polymer-polymer	 chain	 secondary	 bonding	 (e.g.	 hydrogen	 bonding),	 forming	 instead	
secondary	 bonds	 with	 the	 polymer	 chains	 [16].	 Obviously,	 the	 plasticizer	 has	 to	 be	
compatible	with	 the	polymer	 and	 the	other	 components	of	 the	 formulation	and	 the	
optimization	 of	 its	 concentration	 is	 a	 crucial	 factor.	 The	 plasticizer	 concentration	
influences	the	Tg	reduction	and,	therefore,	the	characteristic	of	the	final	matrix	(e.g.	the	
higher	 the	 plasticizer	 concentration,	 the	 higher	 the	 reduction	 in	 the	 polymer	 glass	
transition	 temperature).	 Furthermore,	 according	 to	 the	 free	 volume	 theory	 [17],	 the	
higher	the	glass	transition	value,	the	lower	the	mobility	of	the	PSA	and	thus	the	lower	
the	 drug	 release	 rate	 [18].	 It	 is	 clear	 that	 the	 amount	 of	 such	 substance	 must	 be	
optimized	 to	 obtain	 matrices	 with	 the	 desired	 characteristics:	 a	 lower	 amount	 of	
plasticizer	 allows	 to	 produce	 flexible,	 but	 non-sticky	 films,	 while	 increasing	 its	
concentration	 sticky	 polymeric	 matrix	 can	 be	 produced.	 Despite	 that,	 matrices	
exceeding	 in	 plasticizer	 amount	 should	 exhibit	 a	 completely	 viscous	 character,	 thus	
resulting	not	suitable	for	the	design	of	TP.		
In	addition,	tackifiers,	such	as	resins,	are	other	excipients	that	can	be	ideally	added	to	
increase	tack	and	stickiness	of	the	adhesive	surface	[19].		
To	function	properly,	a	PSA	should	exhibit	the	typical	behavior	of	a	viscoelastic	material,	
that	combines	a	 liquid-	and	solid-like	patter	dependent	of	the	applied	frequency	at	a	
given	temperature	[12].	Usually,	at	low	frequency	a	soft	viscoelastic	material	behaves	
like	a	viscous	liquid	(the	viscous	modulus	is	higher	that	the	elastic	one),	while	at	high	
frequency	 the	 elastic	 modulus	 prevails	 on	 the	 viscous	 one,	 denoting	 a	 solid-like	
behavior.	The	extent	of	viscoelasticity	is	crucial	in	order	to	relax	stresses,	easily	create	a	
molecular	 contact	 and	 dissipate	 energy	 upon	 debonding	 and	 it	 is	 strictly	 related	 to	
adhesive	properties	of	a	patch,	as	referred	to	bond	formation	as	well	as	bond	separation	
[14].	 The	 interpretation	of	 these	 features	demonstrates	 that	 low	 frequencies	 (in	 the	
0.005-0.05	rad/s	range)	can	be	related	to	tack,	while	high	frequencies	(ranged	between	
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100	and	1000	 rad/s)	 can	be	 related	 to	 the	peeling	process	 [20].	As	a	matter	of	 fact,	
during	the	bonding	phase	(tack),	the	adhesive	matrix	should	behave	like	a	viscous	liquid	
to	favor	its	spreading	onto	the	skin	and	to	form	good	molecular	contact	under	a	lightly	
applied	pressure.	Conversely,	during	the	debonding	process	 from	the	skin	 (peel),	 the	
adhesive	 should	 behave	 like	 a	 cohesive	 solid	 to	 ensure	 complete	 removal	 without	
leaving	any	residue	[21].	Furthermore,	a	patch	should	remain	attached	to	the	skin	for	
the	entire	 treatment	period,	 it	 should	not	present	 an	overspreading	of	 the	adhesive	
matrix	beyond	the	boundaries	and	it	should	not	leave	any	residues	upon	removal.	The	
shear	 resistance	 is	 a	 slightly	 higher	 rate	 process	 than	 tack,	 occurring	 at	 frequencies	
ranging	between	0.05	and	0.5	rad/s	[20].		
Another	common	criterion	should	be	satisfied:	a	suitable	PSA	should	present	an	elastic	
modulus	value	at	1	Hz	lower	than	0.1	MPa	allowing	to	reach	a	sufficient	level	of	adhesion	
(Dahlquist	 criterion)	 [22].	Materials	with	 elastic	moduli	 exceeding	 this	 criterion	have	
poor	 adhesive	 characteristics	 due	 to	 their	 inability	 to	 dissipate	 energy	 via	 viscous	
contributions	or	to	deform	to	make	good	contact	with	the	surface.	They	also	show	a	
high	peak	adhesive	force,	but	fail	quickly	upon	further	strain	(brittle	failure,	without	fibril	
formation)	[21].		
Failure	mechanisms	which	occurs	during	the	detachment	of	the	patch	from	the	skin	are	
strongly	 dependent	 on	 the	 rheological	 properties	 of	 the	 PSA	 [19].	 Indeed,	 the	
viscoelastic	 characteristics	 of	 a	 PSA	 control	 its	 deformation	 and	break	 of	 fibrils	 [23].	
Regarding	TP,	two	mains	failure	mechanisms	can	occur,	namely	adhesive	and	cohesive	
failures.	 The	 first	 one	 occurs	 at	 the	 interface	 between	 the	 adhesive	 layer	 and	 the	
substrate;	 in	 this	 case,	 the	 deformation	 of	 the	 layer	 is	 low	 with	 mainly	 lateral	
propagation	and	coalescence	of	the	initial	cavities	along	the	interface.	The	latter	one	
occurs	in	the	bulk	of	the	adhesive	layer,	allowing	the	debonding	process	to	be	governed	
by	viscous	flow.	Since,	if	this	latter	detachment	pattern	occurs	after	the	peeling	process,	
some	adhesive	residues	can	be	noticed	on	the	skin,	an	adhesive	failure	is	mandatory,	so	
that	patch	will	not	leave	any	residues	after	the	detachment.		
Generally,	 transdermal	 route	 of	 administration	 is	 limited	 to	 drugs	 with	 peculiar	
physicochemical	 characteristics.	 Drug	 penetration	 across	 the	 skin	 is	 primarily	
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determined	by	its	solubility,	molecular	structure	and	lipophilicity.	As	a	matter	of	fact,	
smaller	 compounds	 diffuse	 readily	 across	 the	 stratum	 corneum	 than	 larger	 ones.	
Indeed,	maximum	fluxes	of	drugs	with	molecular	weights	greater	than	500	Daltons	are	
very	low.	A	modest	level	of	lipophilicity,	corresponding	to	a	log	P	ranging	between	1-3,	
coupled	with	finite	oil	and	water	solubility	are	ideal	characteristics	for	good	drug	skin	
penetration.	An	optimal	drug	diffusion	through	the	skin	is	also	reached	with	molecules	
that	present	a	melting	point	lower	than	200	°C.	Finally,	usually	transdermal	drug	delivery	
systems	are	used	for	drugs	which	are	extremely	potent,	requiring	a	dosage	of	only	few	
mg	[24].		
In	addition,	for	both	the	dosage	forms,	namely	TP	and	FFS,	the	drug	release	rate	and	the	
subsequent	extent	of	drug	that	can	ideally	permeate	through	the	skin	(i.e.	bioavailability	
and	efficacy)	depend	sensitively	on	the	composition	of	the	formulation.		
The	 release	 profiles	 of	 an	 active	 substance	 from	 a	 polymeric	 matrix	 depend	 on	 its	
diffusion	within	the	matrix	itself	[25].	The	mobility	of	the	polymer	chains	and,	therefore,	
the	grade	of	viscoelasticity	result	a	key	factor	influencing	the	drug	release	rate	[18].	In	
particular,	 a	 more	 liquid	 character	 of	 the	 formulation	 can	 weaken	 the	 interaction	
between	the	polymer	chains	and	expand	the	free	volume,	thus	resulting	in	a	faster	drug	
release	[26].		
Moreover,	 the	 possible	 interaction	 between	 the	 drug	 and	 the	 polymeric	 matrix	 is	
considered	the	main	factor	influencing	the	drug	skin	permeation	[27].	In	the	case	of	FFS,	
both	the	evaporation	rate	of	the	vehicle	and	the	thermodynamic	activity	of	the	drug	
influence	 the	 theoretical	 amount	 of	 drug	 that	 can	 permeate	 the	 skin.	 It	 is	 generally	
recognized	 that	 drug	 supersaturation	 in	 topical	 dosage	 forms	 can	 improve	 the	
permeation	 of	 the	 drug	 itself.	 In	 supersaturated	 formulations,	 the	 thermodynamic	
activity	of	the	drug	is	increased,	thus	enhancing	the	skin	penetration	[28].	On	the	other	
hand,	 supersaturated	 formulations	are	 thermodynamically	 instable,	 causing	 the	drug	
crystallization	over	time,	which	reduces	its	bioavailability	for	the	partition	through	the	
skin	[29].	Since	FFS	become	supersaturated	after	dose	actuation,	they	are	transiently	
drug	 supersaturated	 systems	 and	 the	 drawback	 of	 the	 thermodynamic	 instability	 of	
supersaturated	systems	could	be	overcome.		
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For	the	physical	stability	of	the	drug,	the	film	forming	polymers	are	chosen	since	they	
act	as	anti-nucleating	agents	and	crystallization	inhibitors	and	prevent	the	crystallization	
of	the	drug,	even	after	solvent	evaporation.	It	has	been	demonstrated	by	Cilurzo	and	co-
authors	 that	 polymethacrylate	 copolymers	 can	 be	 potentially	 used	 as	 crystallization	
inhibitors	in	monolayer	patches	containing	ibuprofen	[30]	and	that	they	can	be	used,	
when	opportunely	plasticized,	as	PSA	to	develop	suitable	TP	[31].	
In	 addition	 to	 the	 functional	 features	 described	 above,	 there	 are	 other	 factor	 to	 be	
considered	 in	 the	 selection	 and	 use	 of	 a	 polymer	 for	 designing	 both	 TP	 and	 FFS.	 In	
particular,	 biocompatibility	 and	 acceptable	 regulatory	 status	 must	 be	 satisfied.	 The	
excipients	should	be	compatible	and	mixable	in	the	overall	formulation	and	the	entire	
system,	namely	polymer(s)	and	excipient(s),	should	be	biologically	inert,	non-irritating	
and	 non-sensitizing	 to	 the	 skin,	 and	 have	 no	 toxicity.	Moreover,	 the	 system	 should	
present	good	resistance	against	water	and	humidity	and	avoid	an	excessive	occlusion	of	
the	skin.	
My	 PhD	project	was	 focused	 on	 the	 study	 of	 two	polymers:	 a	 poly(ethylacrylate-co-
methylmethacrylate-co-trimethylammonioethylmethacrylate	chloride)	belonging	to	the	
class	 of	 acrylic-based	 adhesives	 and	 a	 styrene-block-(ethylene-co-butylene)-block-
styrene	copolymer,	a	styrenic-based	adhesive.	The	former	was	used	to	design	both	TP	
and	FFS,	while	the	latter	was	selected	to	design	TP.	
Even	if	the	feasibility	to	design	topical	dosage	forms	made	of	a	poly(ethylacrylate-co-
methylmethacrylate-co-trimethylammonioethylmethacrylate	chloride),	traded	with	the	
name	 of	 Eudragit®	 RL	 PO	 (EuRL),	 able	 to	 deliver	 several	 drugs	 has	 been	 already	
described,	 their	 characterization	 in	 terms	 of	 mechanical	 behavior	 and	 adhesive	
properties	 is	not	available	 in	 literature.	With	the	aim	to	complete	these	 information,	
several	FFS	and	TP	based	on	EuRL	opportunely	plasticized	and	loaded	with	three	model	
drugs,	namely	ibuprofen,	ketoprofen	and	flurbiprofen,	were	formulated.	The	effect	of	
the	overall	formulative	variables	was	studied,	introducing	also	new	techniques	suitable	
to	 better	 clarify	 their	 influence	 of	 such	 variables	 on	 the	 final	 characteristics	 of	 the	
formulated	 dosage	 forms.	 Relationships	 among	 the	 mechanical	 and	 rheological	
behavior	of	 the	PSA	and	 the	 technological	 properties	 and	 in	 vitro	 biopharmaceutical	
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performances	of	the	final	dosage	forms	were	also	investigated.	
Aiming	to	confirm	that	these	characterizations	are	useful	in	the	development	of	a	patch,	
a	 polymer	with	 completely	 different	 physico-chemical	 and	 structural	 properties	was	
selected.	The	 feasibility	 to	develop	PSA	 for	 the	design	of	TP	based	on	 styrene-block-
(ethylene-co-butylene)-block-styrene	(SEBS)	copolymers	was	studied	by	compounding	
the	polymer	with	an	aliphatic	resin	as	tackifier	and	paraffin	oil	as	plasticizer.	A	systematic	
formulative	study	related	to	PSA	mechanical	and	adhesive	properties	was	performed	to	
investigate	 the	 influence	 of	 SEBS	 and	 tackifier	molecular	weights	 on	 the	 rheological	
pattern	and	debonding	behavior	of	such	PSA.	Ibuprofen	and	nicotine	were	selected	as	
model	drugs	to	formulate	the	TP	and	evaluate	their	technological	characteristics	and	in	
vitro	biopharmaceutical	performances.		
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Abstract	
A	film	forming	system	based	on	EudragitÒ	RL	(EuRL)	was	designed	aiming	to	evidence	
the	relevance	of	formulative	variables	on	the	following	critical	attributes:	film	forming	
rate,	outward	stickiness,	Young	modulus	(Y)	and	in	vitro	drug	skin	permeation.	Different	
solvent	 mixtures	 (acetone	 and	 isopropanol	 in	 the	 range	 from	 10:90	 to	 40:60	 v/v),	
polymer	 concentrations	 (10-30	 %	 w/w),	 and	 plasticizer	 types	 and	 concentrations	
(triacetin	or	tributyl	citrate,	up	to	50%	of	EuRL)	were	evaluated.	EuRL	dissolved	in	80/20	
or	 70/30	 v/v	 isopropanol/acetone	 mixtures	 at	 the	 concentration	 of	 20%	 w/w	 and	
plasticized	with	tributyl	citrate	(20	or	30%	w/w	with	respect	to	polymer)	gave	films	with	
negligible	stickiness	and	Y	lower	than	3	MPa.	This	value	should	assure	an	intimate	and	
prolonged	contact	with	the	skin	since	it	was	significantly	lower	than	Y	of	human	stratum	
corneum	 (55	 MPa).	 The	 optimized	 formulations	 were	 able	 to	 sustain	 the	 skin	
permeation	of	ibuprofen,	ketoprofen	and	flurbiprofen	and	evidenced	the	importance	of	
each	 formulative	 variable.	 In	 particular,	 relatively	 slow	 solvent	 evaporation	 rate	 can	
determine	an	initial	“burst”	effect	and	can	influence	the	drug	permeation	in	the	initial	
hours.	 Conversely,	 when	 the	 solvent	 evaporation	 rate	 is	 not	 discriminant,	 the	
thermodynamic	activity	remains	the	main	parameter	driving	the	skin	permeation.	
	
	
	
	
The	 content	 of	 this	 chapter	 was	 published	 in	 Journal	 of	 Drug	 Delivery	 Science	 and	
Technology	(Gennari	CGM	et	al.,	J.	Drug	Deliv.	Sci.	Tec.	2017,	41:157-163).	
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1.1	Introduction	
The	passive	transport	rate	of	a	molecule	through	the	skin	is	proportionally	related	to	its	
degree	of	saturation	in	the	applied	vehicle	[1].	Therefore,	drug	supersaturation	in	topical	
formulations	can	be	induced	to	improve	the	penetration	into	stratum	corneum.	Systems	
that	 are	 transiently	 drug	 supersaturated,	 namely	 those	 systems	 which	 become	
supersaturated	only	after	dose	actuation,	seem	to	be	more	promising	as	dosage	forms	
compared	to	preformed	drug	supersaturated	patches,	since	the	latter	need	to	maintain	
the	supersaturated	state	during	their	entire	shelf-life.	Transient	supersaturation	entails	
the	reduction	of	drug	solubility	in	the	vehicle	that	is	applied	on	the	skin	surface	and	this	
is	most	commonly	achieved	through	solvent	evaporation	[1].	The	simplest	approach	to	
achieve	this	goal	consists	in	the	design	of	polymeric	film-forming	systems	(FFS)	which	
comprises	 a	 film-forming	 polymer	 dissolved	 in	 a	 volatile	 and	 skin	 tolerated	 solvent.	
When	 they	 are	 applied	 and/or	 sprayed	on	 the	 surface	 of	 the	 skin,	 the	 rapid	 solvent	
evaporation	 leads	 to	 the	 formation	 of	 a	 polymeric	 film	 in	 situ	 [2].	 The	 potential	
advantages	of	 these	dosage	 forms	 reside	not	only	 in	 the	possibility	 to	overcome	 the	
issue	related	to	the	physical	instability	of	a	supersaturated	system,	but	also	in	a	possible	
enhancement	effect	related	to	the	solvent	skin	penetration	during	the	metamorphosis	
of	the	formulation	[3,4].	The	last	claimed	advantage	of	FFS	is	related	to	the	cosmetic	
attributes	 of	 the	 film.	 Indeed,	 many	 patients	 complain	 about	 the	 high	 visibility	 of	
transdermal	patches,	which	are	considered	cosmetically	unattractive,	while	the	formed	
film	is	supposed	to	be	almost	invisible.	
Moving	to	the	formulative	requirements,	a	film-forming	solution	should	exhibit	some	
peculiar	features	related	to	both	the	applied	dosage	form	(i.e.	the	polymeric	solution	
itself)	and	the	final	film.	Firstly,	the	novel	dosage	form	should	quickly	dry	on	the	skin	and	
the	minimum	film	forming	temperature	should	be	below	the	skin	surface	temperature	
(about	32	°C).	Secondly,	the	mechanical	properties	of	the	formed	film	should	overcome	
the	tangential	stress	due	to	the	body	movements.	Finally,	the	formed	film	is	required	to	
be	non-sticky	to	avoid	adhesion	to	the	patient’s	clothes.		
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To	satisfy	these	requirements,	a	broad	range	of	polymers	(e.g.	acrylates,	polyurethane-
acrylates,	cellulose	derivatives,	poly(vinyl	pyrrolidones)	and	silicones)	were	tested	[5,6].	
Among	them,	the	use	of	methyl	methacrylate	copolymers	appears	of	particular	interest	
[5,7-10],	even	if	the	literature	reports	contrasting	results	on	EudragitÒ	RL	(EuRL)	when	
it	was	 compared	 to	another	widely	used	 film	 forming	material,	namely	hydroxyethyl	
cellulose.	 As	 an	 example,	 the	 skin	 permeability	 of	 estradiol	 from	 EuRL	 based	 films	
resulted	 significantly	 lower	 than	 that	 obtained	 with	 the	 cellulose	 ether	 [11].	
Nevertheless,	the	use	of	EuRL	allowed	to	overcome	the	mechanical	issues	associated	to	
films	made	of	 hydroxyethyl	 cellulose.	 Indeed,	 it	was	 demonstrated	 that	 both	 tensile	
strength	 and	 percent	 elongation	 at	 break	 of	 the	 films	 were	 improved	 by	 mixing	 in	
appropriate	 ratio	 cellulose	 and	 EuRL	 [12].	 However,	 a	 systematic	 study	 of	 the	
formulation	variables,	namely	solvent	composition,	polymer	concentration,	nature	and	
amount	of	plasticizers,	on	the	FFS	properties	is	still	lacking.		
The	 current	 work	 aimed	 to	 study	 the	 effect	 of	 formulation	 compositions	 on	
technological	and	biopharmaceutical	properties	of	FFS	based	on	EuRL	solubilized	 in	a	
mixture	of	acetone	and	 isopropyl	alcohol	 in	different	 ratios.	This	volatile	vehicle	was	
selected	since	both	solvents	have	a	regulatory	approval	for	topical	use.		
The	effects	of	solvent	systems	as	well	as	the	addition	of	the	plasticizer,	namely	triacetin	
or	tributyl	citrate,	were	preliminary	evaluated	on	drying	time,	outward	stickiness	and	
mechanical	properties.	In	particular,	since	a	reference	for	the	tensile	properties	of	the	
formed	film	is	not	established,	the	elasticity	of	human	stratum	corneum	was	preliminary	
determined	and	used	as	reference.	
The	performances	of	the	optimal	formulations	were	further	investigated	studying	the	
skin	 permeation	 of	 three	 different	 drugs,	 namely	 flurbiprofen,	 ibuprofen	 and	
ketoprofen.	
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1.2	Materials	and	Methods	
1.2.1	Materials	
EudragitÒ	 RL	 PO	 (poly(ethyl	 acrylate-co-methyl	 methacrylate-co-
trimethylammonioethyl	 methacrylate	 chloride);	 molar	 proportions	 of	 the	 monomer	
units	1:2:0.2;	weight	average	molar	mass	32	kDa,	EuRL)	was	kindly	supplied	by	Rofarma	
Italia	(Italy).	Tributyl	citrate	(TBC)	and	triacetin	(TRI)	were	provided	by	Morflex	(USA)	and	
Sigma	Aldrich	 (Italy),	 respectively.	 Isopropanol	 and	acetone	were	purchased	by	VWR	
International	 (Italy).	 Flurbiprofen	 (FP)	 and	 ketoprofen	 (KP)	 were	 purchased	 from	
Farmalabor	(Italy)	and	S-ibuprofen	(IB)	from	Francis	(Italy).	
All	solvents	were	of	analytical	grade,	unless	specified.	
	
	
1.2.2	Preparation	of	polymeric	FFS	
Film-forming	systems	(FFS)	were	prepared	by	adding	10,	or	20,	or	30	(%,	w/w)	EuRL	to	
different	mixtures	of	isopropanol	and	acetone	(ratios:	90:10,	80:20,	70:30,	60:40	%,	v/v)	
with	or	without	the	selected	plasticizer.	Each	solution	was	stirred	overnight	to	ensure	
the	complete	swelling	of	the	polymer	in	the	solvent	blend.	
FP,	or	IB,	or	KP	were	dissolved	in	the	FFS	at	a	concentration	of	4	%	w/w.	
	
	
1.2.3	Characterization	of	the	polymeric	FFS	
The	 preliminary	 screening	 of	 placebo	 compositions	 was	 carried	 out	 keeping	 in	
consideration	the	FFS	drying	time,	the	stickiness	and	cosmetic	attributes	of	the	formed	
film.	Briefly,	a	small	volume	of	the	formulations	was	applied	with	a	micropipette	onto	a	
plastic	 liner	and	 the	 solvent	was	allowed	 to	evaporate	 to	 form	 the	 film.	The	applied	
volume	was	fixed	at	35	µL/2.5	cm2	as	this	amount	is	small	enough	to	be	applied	without	
flowing	 away	 from	 the	 application	 site.	 No-sticking	 films	 formed	within	 10	min	 and	
showing	good	cosmetic	attributes	were	considered	adequate	for	the	aim	of	this	work.	
Chapter	1	
	 25	
The	drying	time	was	visually	checked	by	evaluating	the	formation	of	a	fingerprint	on	the	
film	 surface.	 This	 approach	 has	 been	 selected	 since	 the	 other	 method	 reported	 in	
literature,	 namely	 the	 use	 of	 a	 glass	 slide	 [5,6],	 did	 not	 permit	 to	 discriminate	 the	
formation	of	a	dried,	but	sticky	film.	The	adhesive	properties	were	preliminary	evaluated	
by	a	thumb	tack	test	[13],	on	the	dry	films	according	to	the	following	score	system:	no	
adhesion,	poor	adhesion	and	good	adhesion.	
Afterwards,	TBC	or	TRI	were	added	to	the	most	promising	FFS	in	order	to	evaluate	the	
effect	of	the	plasticizers	on	the	flexibility	of	films.	To	select	the	plasticizer	concentration,	
the	glass	 transition	temperature	 (Tg)	of	 films	made	by	casting	a	polymeric	mixture	 in	
isopropyl	alcohol,	containing	the	selected	plasticizer	in	different	ratios,	was	evaluated	
by	differential	 scanning	calorimetry	 (DSC)	analysis	 (DSC1	 Instrument,	Mettler-Toledo,	
CH).	Briefly,	20	mg	(±	0.01	mg)	exactly	weighted	samples	were	sealed	in	aluminum	pans	
and	heated	in	inert	atmosphere	(70	ml	min-1	of	N2).	The	reference	was	a	pan	containing	
aluminum	oxide	[10].	The	equipment	was	calibrated	with	an	indium	sample.	Films	were	
scanned	at	20	K/min	from	20	to	80	°C	in	order	to	erase	polymer	thermal	history,	then	
cooled	down	 to	–	50	 °C	 at	 20	K/min	and	 re-heated	up	 to	80	 °C	 at	 20	K/min.	 Tg	was	
calculated	as	the	inflection	point	in	the	second	heating	ramp.		
	
	
1.2.4	Mechanical	testing	
Human	stratum	corneum	isolation.	The	permeation	studies	were	performed	using	the	
abdominal	skin	 from	female	donors,	who	underwent	cosmetic	surgery	and	signed	an	
informed	consent	for	the	use	of	the	biological	sample	for	research	purposes	[14].	After	
removing	the	subcutaneous	fatty	tissue,	the	skin	was	kept	frozen	until	further	use.	For	
the	stratum	corneum	isolation,	skin	sections	were	cut	into	squares	of	about	2.5	cm2	and	
were	 immersed	 in	 water	 of	 60	 °C	 for	 60	 s	 according	 to	 an	 internal	 protocol	 [15].	
Afterwards,	the	epidermis	was	carefully	removed	from	the	underlying	tissue	with	the	
help	of	 forceps	and	visually	 inspected	for	defects.	Then,	 the	epidermis	samples	were	
incubated	for	24	h	at	37	°C	in	a	0.1%	w/v	trypsin	solution	in	pH	7.4	phosphate	buffer	
[15].	 After	 digestion,	 the	 underlying	 tissue	 of	 epidermis	 was	 scraped	 away	 and	 the	
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remaining	stratum	corneum	was	washed	in	cold	MilliQÒ	water.	The	stratum	corneum	
samples	 were	 cut	 in	 8	´	 16	mm	 specimen,	 transferred	 into	 Petri	 dishes	 and	 left	 to	
equilibrate	in	a	humidifier	at	25	°C	and	75%	relative	humidity	using	a	saturated	solution	
of	sodium	chloride,	over	a	12	h	period.	
Film	preparation.	Placebo	films	were	prepared	by	a	solvent	casting	technique	by	using	a	
laboratory-coating	unit	Mathis	LTE-S(M)	(Mathis,	CH),	equipped	with	a	blade	coater.	The	
coating	thickness	was	set	in	order	to	obtain	a	dried	film	of	about	50	μm.	The	FFS	was	
spread	on	the	release	liner	and	dried	at	32	±	1	°C	for	20	min.	Film	samples	were	cut	in	7	
´	20	mm	specimen	and	stored	at	25	°C	until	use.	
Probe	tack	test.	Probe	tack	test	measures	the	force	required	to	separate	the	test	probe	
tip	from	the	film	sample	by	using	a	tensile	testing	machine	equipped	with	a	50	N	cell	
load	 transducer	 (Instron	 5965,	 ITW	 Test	 and	 Measurement	 Italia	 S.r.l.,	 Italy).	 The	
experiments	were	set	according	to	an	internal	standard	procedure	[16].	Briefly,	a	flat	
stainless	steel	probe	(diameter:	6	mm)	was	placed	about	0.05	mm	above	the	sample.	
Then,	the	probe	was	lowered	onto	the	film	surface	and	a	constant	force	of	0.05	N	was	
applied	onto	the	sample	for	5	s	and,	finally,	the	probe	was	removed	at	the	debonding	
rate	of	0.1	mm/s.	The	stress	(σ)	values	for	each	experiment	were	calculated	according	
to	the	following	equation:	
	
σ	=	F/A	 	 	 	 	 	 	 	 	 Eq.	1.1	
	
where	F	is	the	force	registered	during	the	detachment	and	A	is	the	probe	surface	area.	
The	results	are	expressed	as	the	mean	±	SD	of	four	samples	for	each	formulation.	
Tensile	test	-	Stratum	corneum	strips	(8	´	16	mm)	or	film	samples	(7	´	20	mm)	were	
positioned	between	two	pneumatic	jaws	of	the	tensile	testing	machine,	separated	at	a	
distance	of	8	mm.	The	lower	jaw	remains	fixed,	whilst	the	upper	jaw	connected	to	the	
load	cell	mounted	on	top	of	the	crosshead	rises	at	a	speed	of	2	mm	min-1.	Young	modulus	
(Y)	was	calculated	as	the	slope	of	the	linear	portion	of	the	stress-strain	curve.	The	results	
were	expressed	as	force	per	unit	area	(MPa).	Individual	experiments	were	performed	
on	four	samples	of	stratum	corneum	or	film.	
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1.2.5	Thermogravimetric	analysis	
Thermogravimetric	 measurements	 (TGA)	 were	 carried	 out	 using	 a	 TGA	 2050	
Thermogravimetric	Analyzer	(TA	Instruments,	USA).	Samples	of	80	μL	FFS	were	held	at	
32	°C	under	nitrogen	atmosphere	and	mass	losses	versus	time	were	measured	over	1	h.	
The	higher	the	Δm	min-1	value	obtained,	the	faster	the	solvent	evaporation.	
	
	
1.2.6	Polarized	optical	microscopy	
Crystallization	 of	 drugs	 from	 the	 polymeric	 FFS	was	 evaluated	 by	 a	 polarized	 optical	
microscopy	(Axiolab	E	re,	CarlZeiss,	Germany)	equipped	with	10x	objective.	A	suitable	
volume	of	each	solution	was	spread	on	a	microscope	glass	slide	and	allowed	to	dry	in	a	
water	vapor	saturated	chamber	at	32	°C,	to	mimic	the	conditions	of	the	skin	penetration	
experiments.	The	presence	or	absence	of	drug	crystals	was	noted.	
	
	
1.2.7	In	vitro	drug	permeation	
The	human	epidermis	samples	were	prepared	as	described	above.	Prior	to	experimental	
use,	the	integrity	was	assessed	measuring	their	electrical	resistance	(voltage:	100	mV,	
frequency:	 100	 Hz;	 Agilent	 4263B	 LCR	 Meter,	 Microlease,	 Italy).	 Samples	 with	 an	
electrical	 impedance	 resistance	 higher	 than	 30	 KΩ·cm2	 were	 used	 for	 the	 in	 vitro	
permeation	experiments	[15].	
The	epidermis	sample	was	mounted	on	the	Franz	diffusion	(PermeGear,	USA)	cell	with	
an	effective	penetration	area	of	0.636	cm2.	The	receptor	compartment	(volume:	~	3.0	
mL)	was	filled	with	degassed	0.9%	w/v	NaCl	solution.	Special	care	was	given	to	avoid	air	
bubbles	between	the	buffer	and	the	epidermis	in	the	receptor	compartment.	The	upper	
and	 lower	 parts	 of	 the	 vertical	 Franz	 cell	 were	 sealed	 with	 ParafilmÒ	 and	 fastened	
together	by	means	of	a	 clamp.	Volumes	of	10	μL	FFS	were	applied	uniformly	on	 the	
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epidermis	 sample	 as	 donor	phase.	 The	 system	was	 kept	 at	 37	 ±	 1	 °C	by	means	of	 a	
circulating	water	bath	so	that	the	skin	surface	temperature	was	at	32	±	1	°C	and	the	
receiver	medium	was	continuously	maintained	under	stirring	with	a	magnetic	bar.		
The	experiments	(three	replicates	per	formulation)	were	performed	over	a	24	h	period	
under	 non-occlusive	 conditions.	 During	 this	 period,	 200	 μL	 samples	 were	 drawn	 at	
predetermined	intervals	and	replaced	by	aliquots	of	fresh	receptor	fluid.	Sink	conditions	
were	maintained	throughout	the	experiment.	Samples	were	analysed	by	HPLC	according	
to	the	methods	described	below.		
The	 cumulative	amount	permeated	 through	 the	 skin	per	unit	of	 area	was	 calculated	
from	 the	 concentration	of	 each	 substance	 in	 the	 receiving	medium	and	plotted	as	 a	
function	of	time.		
The	average	flux	(J)	was	calculated	over	the	1-5	h	period	of	time.		
	
	
1.2.8	Drug	assay	
The	drug	 concentrations	 in	 the	 receiving	media	were	determined	by	HPLC	assay	 (HP	
1100,	Chemstation,	Hewlett	Packard,	USA).	The	following	chromatographic	conditions	
were	used:	Column:	HyperCloneTM	5µm	BDS	C18	130,	150´4.6	mm	(Phenomenex,	USA);	
mobile	 phase:	 acetonitrile/pH	 2.6	 water	 (60/40,	 %	 v/v);	 flow	 rate:	 1.5	 mL/min;	
wavelengths:	246	nm	(FP),	225	nm	(IB)	or	255	nm	(KP);	temperature:	25	°C;	 injection	
volume:	20	µL.	The	drug	concentrations	were	determined	from	standard	curves	in	the	
0.1-50.0	µg/mL	range.	The	retention	time	was	approximately	2.5	minutes	for	FP,	3.0	min	
for	 IB	 and	 1.8	min	 for	 KP.	 The	method	 provided	 good	 precision	 and	 linearity	 in	 the	
required	concentration	range	(R2=1.00000	for	FP,	R2=0.99995	for	IB,	R2=0.99999	for	KP).	
	
	
1.2.9	Statistical	analyses	
Tests	for	significant	differences	between	means	were	performed	by	ANOVA	followed	by	
Tukey	post	hoc	analyses	(OriginPro	2015,	OriginLab,	USA).		
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1.3	Results	and	Discussion	
1.3.1	Formulation	study	
The	preliminary	screening	of	placebo	compositions	was	carried	out	in	vitro	keeping	in	
consideration	the	FFS	drying	time,	the	stickiness,	measured	qualitatively	by	thumb	tack	
test,	and	the	cosmetic	attributes	of	the	formed	film.	No-sticking	films	formed	within	10	
min	and	showing	good	cosmetic	attributes	were	considered	adequate	for	the	aim	of	this	
work.	
The	formulations	prepared	with	the	highest	EuRL	concentration	or	an	acetone	content	
higher	than	30%	required	more	than	10	min	to	completely	dry.	On	the	other	hand,	the	
lowest	polymer	concentration	did	not	allow	the	formation	of	a	uniform	film.	Thus,	20%	
w/w	EuRL	solutions	in	isopropanol/acetone	at	the	ratios	in	the	90:10-70:30	range	were	
considered	worthy	to	design	a	FFS	formulation.	
Since	EuRL	presents	a	Tg	at	about	63	°C,	 the	addition	of	a	plasticizer	 is	mandatory	to	
decrease	 Tg	 below	 the	 skin	 surface	 temperature	 (~	 32	 °C),	 in	 order	 to	 satisfy	 the	
requirements	of	flexibility	and	elongation	necessary	to	assure	a	proper	skin/dosage	form	
contact.	On	the	other	hand,	an	excess	of	plasticizer	concentration	in	the	formed	film	can	
affect	its	properties	since	it	is	generally	recognized	that	when	the	Tg	is	about	25-45	°C	
lower	than	the	application	temperature	the	material	can	become	sticky	[17].	Since	the	
skin	surface	temperature	is	about	32	°C,	it	is	reasonable	to	suppose	that	materials	with	
a	Tg	lower	than	-10	°C	are	sticky	[8].	On	the	bases	of	these	considerations	we	established	
that	the	Tg	of	the	formed	film	should	be	in	the	+30	°C	to	-5	°C	range.		
In	order	to	avoid	the	influence	of	the	solvent	and	the	drying	process,	Tg	was	calculated	
on	the	second	heating	ramp.	As	summarized	in	Table	1.1,	the	optimal	concentration	of	
both	the	selected	plasticizers	was	about	20-30%	w/w.		
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Table	1.1	-	EuRL	glass	transition	temperatures	(Tg)	obtained	by	DSC	analysis	
dependent	on	the	plasticizer	content.	
EuRL	
(%,	w/w)	
TBC	
(%,	w/w)	
TRI	
(%,	w/w)	
Tg	
(°C)	
100	 -	 -	 63	±	1	
90	 10	 -	 43	±	4	
80	 20	 -	 27	±	1	
70	 30	 -	 19	±	1	
60	 40	 -	 -20	±	1	
50	 50	 -	 -26	±	2	
90	 -	 10	 40	±	2	
80	 -	 20	 18	±	1	
70	 -	 30	 13	±	2	
60	 -	 40	 -7	±	5	
50	 -	 50	 -16	±	1	
	
	
However,	the	outward	stickiness	can	be	influenced	not	only	by	the	extent	of	plasticizer,	
but	also	by	the	solvent	composition,	which	can	 lead	to	a	different	three	dimensional	
organization	of	the	polymeric	chains	during	the	in	situ	formation	of	the	film.	Hence,	the	
stickiness	of	the	preformed	films	was	also	determined	by	probe	tack	test	(Tab.	1.2).
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Table	1.2	-	Tackiness	(σ)	and	Young’s	m
odulus	(Y)	of	film
s	obtained	from
	FFS	m
ade	of	20%
	EuRL	in	
different	solvent	system
s	and	plasticized	by	different	content	of	tributyl	citrate	(TBC)	or	triacetin	(TRI).	
Form
.	
code	
Isopropanol/acetone	
TBC	
(%
,	w
/w
)	
TRI	
(%
,	w
/w
)	
Drying	tim
e	
(m
in)	
σ	
(kPa)	
Y
§	
(M
Pa)	
1	
90/10	
20	
-	
<	5	
3.61	±	0.52	
n.d.	
2	
90/10	
30	
-	
<	10	
4.96	±	1.63	
n.d.	
3	
90/10	
-	
20	
<	5	
5.50	±	0.18	
n.d.	
4	
90/10	
-	
30	
<	10	
10.37	±	2.88	
n.d.	
5	
80/20	
20	
-	
<	5	
0.62	±	0.16	
3.0	±	0.3	
6	
80/20	
30	
-	
<	10	
0.96	±	0.33	
0.5	±	0.0	
7	
80/20	
-	
20	
<	5	
0.66	±	0.16	
31.9	±	10.5	
8	
80/20	
-	
30	
<	10	
0.69	±	0.23	
<	0.1	
9	
70/30	
20	
-	
<	5	
0.31	±	0.00	
3.7	±	0.5	
10	
70/30	
30	
-	
<	10	
12.63	±	3.24	
n.d.	
11	
70/30	
-	
20	
<	5	
0.28	±	0.01	
40.5	±	13.1	
12	
70/30	
-	
30	
<	10	
6.05	±	2.53	
n.d.	
n.d.:	not	determ
ined.		
§:	Young’s	m
odulus	of	the	hum
an	epiderm
is	=	55.4	±	13.0	M
Pa.	
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Formulations	at	the	highest	isopropanol	content	caused	the	formation	of	films	adhesive	
on	the	outer	surface,	independently	of	the	plasticizer	content.	A	similar	behavior	was	
evident	 for	 films	 plasticized	 by	 30%	 w/w	 TBC	 or	 TRI	 obtained	 from	 a	 70:30	 v/v	
isopropanol/acetone	solution	and,	therefore,	the	formulations	nos.	1-4,	7,	8,	10-12	were	
discarded	(Tab.	1.2).		
The	tensile	properties	of	the	selected	formulations	were	determined	and	compared	to	
those	of	the	human	stratum	corneum.	In	this	case,	the	acceptance	criterion	was	defined	
so	that	the	elastic	modulus	of	the	formulation	should	not	exceed	that	of	the	stratum	
corneum	to	assure	an	intimate	and	prolonged	contact	after	topical	application.	Indeed,	
the	 film	 should	 possess	 tensile	 properties	 that	 allow	 to	 accommodate	 normal	 skin	
mechanical	responses	due	to	tangential	stresses	related	to	body	motions	[9,18].	
When	comparing	data	reported	in	literature	about	mechanical	properties	of	skin,	there	
is	a	quite	evident	variation,	because	of	the	specimen	location,	the	variability	of	biological	
tissues	and	the	experimental	set	ups	(in	vitro	or	in	vivo).	Overall,	the	results	enlisted	in	
Table	1.2	are	included	within	the	ranges	found	in	literature	for	the	in	vitro	tensile	tests.	
Indeed,	depending	on	the	anatomic	origin	of	samples	and	operative	conditions,	the	in	
vitro	values	of	elastic	modulus	ranged	from	3-150	MPa	[19].	
Therefore,	a	maximum	value	of	3	MPa	was	established	for	the	selection	of	the	suitable	
formed	film	in	agreement	with	the	threshold	selected	for	other	applications	of	films	on	
the	skin	and,	therefore,	assumed	as	ideal	to	cover	the	range	of	elastic	skin	response	[18].	
The	addition	of	20%	w/w	of	TBC	or	TRI	allowed	obtaining	films	with	the	Young’s	moduli	
lower	 than	 that	 of	 the	 skin	 (Tab.	 1.2)	 and,	 therefore,	 an	 appropriate	 flexibility.	 As	
expected,	the	higher	the	plasticizer	concentration,	the	lower	the	Young’s	modulus	value	
of	the	formed	film	(Tab.	1.2).	The	data	also	underlined	that	the	Young’s	modulus	was	
not	influenced	by	the	organic	solvent	composition,	but	only	by	the	type	and	content	of	
plasticizer;	in	particular,	TBC	resulted	more	effective	in	reducing	the	Young’s	modulus	
values.	In	general,	the	current	data	were	in	agreement	also	with	the	results	obtained	by	
using	nanoindentation	to	determine	the	elastic	moduli	of	various	films	prepared	with	
EudragitÒ	RS	dissolved	in	ethanol,	with	or	without	a	plasticizer	and/or	betamethasone	
17-valerate	[9].	Moreover,	the	authors	provided	that	the	presence	of	the	drug	in	these	
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formulations	 had	 no	 significant	 effect	 on	 the	mechanical	 properties	 of	 the	 films	 [9].	
Despite	the	elastic	moduli	determined	by	AFM	(Y	=	0.3	GPa)	were	different	an	order	of	
magnitude	to	that	determined	by	texture	analysis	in	the	current	set	of	experiments	(Y	=	
55	MPa),	the	minimum	plasticizer	concentration	needed	to	obtain	a	flexible	formulation	
was	 comparable,	 independently	 of	 the	 technique.	 However,	 in	 the	 cited	 work	 the	
adhesive	properties	were	not	 taken	 in	 consideration.	Our	 results	 suggest	 that	 in	 the	
formulation	of	a	FFS	three	different	techniques,	namely	DSC,	probe	tack	test	and	tensile	
test,	 should	 be	 combined	 to	 identify	 the	 optimal	 range	 of	 each	 main	 formulative	
variables	(i.e.	the	polymer	concentration,	the	type	and	extent	of	plasticizer	and	volatile	
solvent	composition).		
The	optimal	FFSs	resulted	the	formulations	nos	5,	6	and	9.	They	were	loaded	with	4	%	
w/w	FP,	IB	or	KP	(Tab.	1.3)	to	investigate	the	skin	permeation	process	of	such	model	
drugs
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Table	1.3	-	Perm
eation	data	obtained	by	applying	as	donor	phase	FFS	loaded	w
ith	flurbiprofen	(FP),	ketoprofen	(KP)	or	S-
ibuprofen	(IB)	and	drying	rate	expressed	as	m
ass	variation	(Dm
)	determ
ined	by	TGA	over	tim
e.	
Form
.	
code	
Drug	conc.	
(%
,	w
/w
)	
Isopropanol/acetone	
TBC	
(%
)	
Vol.*	
(µL)	
Q
24	
(µg/cm
2)	
J	
(µg/cm
2/h)	
Δm
/t	
(%
	m
in
-1)	
FP1	
4	
80/20	
20	
10	
36.43	±	4.89	
2.19	±	0.51	
0.991	±	0.031	
100	
117.83	±	13.34	
5.78	±	0.14	
FP2	
4	
70/30	
20	
10	
25.23	±	6.57	
1.49	±	0.40	
1.366	±	0.008	
FP3	
4	
80/20	
30	
10	
11.39	±	5.50	
0.62	±	0.27	
1.383	±	0.015	
FP4	
2	
80/20	
20	
20	
24.80	±	5.69	
1.64	±	0.86	
1.139	±	0.040	
FP5	
8	
80/20	
20	
10	
73.50	±	6.14	
3.90	±	0.60	
1.167	±	0.079	
KP1	
4	
80/20	
20	
10	
34.62	±	15.71	
1.98	±	0.78	
1.208	±	0.042	
KP2	
4	
70/30	
20	
10	
40.49	±	4.13	
3.19	±	0.97	
1.327	±	0.008	
KP3	
4	
80/20	
30	
10	
39.06	±	0.52	
3.58	±	1.68	
1.071	±	0.093	
IB1	
4	
80/20	
20	
10	
30.21	±	9.63	
1.33	±	0.46	
1.242	±	0.016	
IB2	
4	
70/30	
20	
10	
50.35	±	2.74	
3.31	±	0.29	
1.172	±	0.004	
IB3	
4	
80/20	
30	
10	
71.33	±	13.14	
4.62	±	0.87	
1.063	±	0.024	
*	Solution	loaded	in	the	donor	com
partm
ent	of	Franz	cell.	
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1.3.2	In	vitro	human	skin	permeation	
Drug	permeation	profiles	from	FFS	are	illustrated	in	Figure	1.1a-c.		
	
	
Figure	1.1	-	Drug	permeation	profiles	from	FFS	obtained	by	applying	10	μL	FFS	loaded	by	(a)	FP,	
(b)	IB	and	(c)	KP	on	the	Franz	diffusion	cells.	Error	bars	represent	standard	deviation.	
	
	
In	 case	 of	 FFS	 loaded	 with	 FP	 and	 IB,	 both	 the	 solvent	 mixture	 and	 the	 plasticizer	
influenced	the	drug	permeation	profiles,	but	in	different	ways.	The	highest	amount	of	
FP	permeated	was	obtained	using	the	isopropanol/acetone	mixture	at	the	volume	ratio	
of	80:20	v/v	(formulation	FP1,	Tab.	1.3),	which	showed	also	an	initial	“burst”	effect.	This	
result	 could	 be	 explained	 on	 the	 basis	 of	 the	mechanism	 of	 drug	 deposition	 from	 a	
volatile	 solvent	 system	 which	 carries	 the	 drug	 into	 the	 upper	 layer	 of	 the	 stratum	
corneum	prior	to	evaporation.	The	longer	the	contact	time,	the	deeper	the	penetration	
of	 the	 solvent	 and	 drug	 into	 the	 epidermis.	 A	 too	 fast	 evaporation	 rate	 leads	
consequently	to	a	short	residence	time	that	can	limit	the	drug	penetration	[20,21].	In	
other	words,	the	drug	absorption	rate	can	be	expected	to	be	inversely	proportional	to	
the	evaporation	rate	of	the	volatile	solvent.	Comparing	the	permeability	results	of	FP	
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loaded	formulations	to	the	volatile	solvent	evaporation	data	obtained	by	TGA	analysis	
(Tab.	1.3),	FP1	showed	a	 lower	evaporation	rate	 than	FP2	and	FP3,	 representing	 the	
main	driving	force	 influencing	drug	permeability.	The	above-suggested	mechanism	of	
drug	delivery	from	a	FFS	vehicle	can	also	help	to	explain	the	permeation	profile	from	
FP1:	the	initial	burst	effect	can	be	ascribed	to	the	slow	evaporation	rate	of	the	solvent	
system	that	subsequently	enhances	the	drug	flux	and	the	total	drug	permeated	amount.	
Moreover,	the	FP	permeation	appears	negatively	influenced	by	the	plasticizer	content:	
the	higher	the	plasticizer	content	 (FP3),	 the	 lower	the	permeated	amount	 (Tab.	1.3).	
This	result	cannot	be	related	to	the	TGA	data,	since	there	were	no	significant	differences	
between	the	solvent	evaporation	rate	of	FP3,	namely	the	formulation	with	the	highest	
plasticizer	content,	and	FP2,	namely	the	formulation	prepared	with	the	highest	acetone	
content.	Therefore,	this	feature	might	be	explained	taking	into	account	the	solubilizing	
effect	of	the	plasticizer,	which	reduced	the	drug	thermodynamic	activity	in	the	film	and,	
consequently,	decreased	its	flux	through	the	skin	(Tukey	test,	p	=	0.048).		
In	 the	 case	 of	 IB	 loaded	 FFS,	 the	 drug	 permeation	was	 positively	 influenced	 by	 the	
plasticizer	concentration	(IB3)	and	the	drug	permeation	profiles	followed	the	rank	order:	
IB3>IB2>IB1	(Tukey	test,	p	<	0.01).	Since	IB	is	freely	mixable	with	EuRL	[22],	the	key	factor	
governing	 the	 extent	 of	 skin	 permeation	 in	 the	 first	 hours	 appears	 the	 solvent	
evaporation	 rate.	 Indeed,	 the	 faster	 the	 evaporation	 rate,	 the	 lower	 the	 permeated	
amount	 (Tab.	1.3).	 It	 can	be	also	supposed	 that	 the	addition	of	TBC	could	affect	 the	
solubility	of	the	drug	in	the	matrix,	causing	an	improvement	of	the	partition	of	IB	from	
the	film	toward	the	skin.		
Finally,	the	three	formulations	loaded	with	KP,	which	presented	the	same	evaporation	
rate,	 showed	 no	 significant	 differences	 in	 their	 drug	 permeation	 profiles	 (One	 way	
ANOVA,	p=0.29,	Tab.	1.3),	suggesting	that	only	the	skin	barrier	properties	dictated	the	
diffusion	process.	
Aiming	 to	 investigate	 the	 effect	 of	 drug	 concentration	 on	 the	 performances	 of	 drug	
loaded	FFS,	the	formulation	FP1,	which	presented	a	“burst”	effect,	was	selected	to	carry	
out	 further	 in	 vitro	 experiments,	 varying	 or	 the	 donor	 phase	 volume	 or	 the	 drug	
concentration	in	the	FFS.	In	particular,	the	following	modifications	of	the	experimental	
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protocol	 were	 considered:	 (a)	 increasing	 the	 applied	 volume	 to	 100	 μL,	 while	
maintaining	constant	the	drug	concentration	at	4%	w/w;	or	(b)	increasing	the	volume	of	
the	donor	phase	(20	μL	 instead	of	10	μL)	and	decreasing	the	drug	concentration	(2%	
w/w)	in	the	FFS;	or	(c)	increasing	the	drug	concentration	(8%	w/w)	and	applying	10	μL	
of	FFS	as	donor	phase.	As	expected,	both	the	increase	of	drug	concentration	and	the	
applied	 volume	 led	 to	 an	 improvement	 of	 the	 FP	 amounts	 permeated	 through	 the	
human	epidermis	(Tuckey	test,	p	<	0.05,	Tab.	1.3).	It	is	noteworthy	that	the	flux	of	FP	by	
the	film	containing	highest	drug	concentration	changed	over	time.	Indeed,	the	FP	flux	
was	high	over	the	first	five	hours	following	application,	but	it	was	reduced	between	7	
and	24	h	(Fig.	1.2).	
	
	
Figure	1.2	-	FP	permeation	profiles	from	FFS	obtained	by	varying	the	donor	phase	volume	(10	
μL	or	100	μL	FP1)	or	by	varying	the	drug	concentration	in	the	donor	phase,	namely	10	μL	at	2%	
w/w	(FP4),	4%	w/w	(FP1)	and	8%	w/w	(FP5).	Error	bars	represent	standard	deviation.	
	
	
A	 similar	 pattern	 was	 also	 reported	 for	 methylphenidate	 films	 having	 similar	
composition	[23]	and	it	was	attributed	to	a	drug	crystallization,	which	reduced	the	drug	
availability	to	the	partition	from	the	donor	compartment	toward	the	stratum	corneum.	
Indeed,	the	film,	after	dismounting	from	the	Franz	diffusion	cell,	showed	some	signs	of	
cloudiness	and	small	crystals	were	observed	by	light	microscopy	on	dried	film	8	h	after	
having	deposited	on	glass	slide	a	FFS	loaded	by	8%	w/w	(data	not	shown).	
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Conversely,	 the	concomitant	 increase	of	 the	applied	volume	and	the	decrease	of	 the	
drug	 concentration,	 to	 apply	 the	 same	 dose	 (see	 formulations	 FP1	 (10	 µL)	 and	 FP4	
(Tukey	test,	p	=	0.025,	Tab.	1.3),	significantly	affected	both	the	FP	flux	and	the	amount	
permeated	after	24	h.	This	might	be	attributed	to	a	lower	thermodynamic	activity	of	the	
drug	 in	 the	 film,	 confirming	 that	 it	 is	 the	 more	 relevant	 feature	 influencing	 skin	
permeation,	when	the	evaporation	rate	can	be	assumed	comparable.	
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1.4	Conclusions	
This	work	allowed	to	individuate	the	formulative	space	to	design	a	film	forming	solution	
based	on	EuRL	and	evidenced	that	not	only	the	drug	thermodynamic	activity,	but	also	
the	solvent	evaporation	rate	significantly	influenced	the	skin	permeation	from	FFS.	The	
relevance	of	 these	two	formulation	parameters	 is	strictly	 related	to	the	 loaded	drug,	
even	within	the	same	class	of	compounds	(e.g.	in	our	case	the	aryl-propionic	acids).	In	
particular,	 the	 vehicle	 composition,	 apart	 from	 its	 function	 to	 solubilize	 the	 other	
excipients	and	the	drug,	can	influence	the	initial	delivery	of	drug	into	the	skin,	according	
to	the	solvent	evaporation	rate:	the	lower	the	evaporation	rate,	the	higher	the	“burst”	
effect	and	the	flux	in	the	initial	hours	following	drug	application.		
The	second	investigated	aspect	deals	with	the	influence	on	skin	permeation	of	the	drug	
concentration	and	the	applied	amount	of	dosage	form.	In	this	case,	the	main	criticism	is	
related	to	the	drug	crystallization	that	can	occur	also	in	relatively	short	period	of	time	
affecting	the	whole	permeation	process	through	the	skin,	as	evidenced	in	the	case	of	
the	FSS	loaded	with	8%	w/w	FP.	
Finally,	 the	 obtained	 data	 evidenced	 that	 the	 critical	 attributes	 that	 should	 be	
considered	in	the	design	of	film	forming	formulations	are	the	outward	stickiness,	which	
was	scantly	investigated	till	now,	and	the	elasticity	of	the	formed	film,	other	than	the	
film	forming	rate	and	the	biopharmaceutical	performances.	
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Abstract	
EudragitÒ	RL	(EuRL)	matrices	have	been	proposed	to	release	a	drug	to	the	skin.	However,	
no	 information	 is	 available	 on	 both	 viscoelastic	 and	 adhesive	 properties	 of	 such	
compositions.	 This	 work	 focuses	 on	 the	 evaluation	 of	 both	 rheological	 and	 texture	
properties	of	EuRL	differently	plasticized	with	tributyl	citrate	(TBC)	or	triacetin	(TRI)	in	
order	 to	 design	 a	 pressure	 sensitive	 adhesive	 suitable	 for	 transdermal	 patch	
preparation.	The	patch	adhesive	properties	(i.e.	tack,	peel	adhesion	and	shear	adhesion)	
as	well	as	 its	 in	vitro	biopharmaceutical	performances	were	determined	after	 loading	
ibuprofen,	ketoprofen	or	flurbiprofen.	The	addition	of	40-60%	w/w	TBC	or	40-50%	w/w	
TRI	 to	 EuRL	 permitted	 to	 obtain	 matrices	 with	 the	 desired	 adhesive	 properties.	
Moreover,	 the	 increase	 of	 plasticizer	 content	 and	 loading	 of	 the	 drug	 reduced	 the	
relaxation	time	(tR).	Consequently,	the	shear	adhesion	values	decreased	and	the	in	vitro	
drug	release	constants	(k)	increased.	Indeed,	the	k	values	from	patches	containing	TBC	
were	 lower	 than	 the	 corresponding	 with	 TRI	 because	 of	 the	 lower	 fluidity	 of	 such	
matrices.	In	conclusion,	the	60/40	EuRL/TBC	binary	blend	is	suitable	for	the	design	of	
transdermal	patches	 since	 the	 in	 vitro	 drug	permeability	of	 the	 three	 selected	drugs	
appeared	comparable	to	those	described	in	literature	for	marketed	drug	products.	
	
	
	
The	 content	 of	 this	 chapter	 was	 published	 in	 European	 Journal	 of	 pharmaceutical	
Sciences	(Quaroni	GMQ	et	al.,	Eur.	J.	Pharm.	Sci.	2018,	111:238-246).	
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2.1	Introduction	
Transdermal	patches	and	medicated	plasters	are	pharmaceutical	preparations	designed	
to	provide	a	prolonged	delivery	of	drugs	to	the	skin	to	achieve	a	systemic	or	local	effect,	
respectively.	Usually,	they	are	drug-in-adhesive	systems,	in	which	the	drug	is	dispersed	
and/or	dissolved	in	a	pressure-sensitive	adhesive	(PSA)	matrix.	PSAs	are	defined	as	soft	
polymeric	materials	that	display	an	instantaneous	adhesion	on	almost	any	surface	by	
simple	 contact	 under	 a	 light	 pressure	 and	 that	 can	 ideally	 be	 detached	 from	 the	
substrate	without	any	residue	[1].	
The	efficiency	of	the	therapeutic	treatment	by	these	dosage	forms	is	related	not	only	to	
their	ability	to	release	the	drug	through	the	skin,	but	also	to	their	complete	skin	contact	
over	 the	whole	delivery	 surface	 for	 the	 entire	 treatment	period.	 If	 the	patch	 lifts	 or	
partially	 detaches,	 the	 effective	 contact	 area,	 and	 thus	 the	 drug	 absorption,	 is	
unpredictable	and	therapeutic	failure	can	occur	[2].	
The	 adhesive	 properties	 of	 a	 PSA	 strongly	 depend	 on	 their	 viscoelastic	 properties.	
Viscoelastic	materials	are	needed	in	order	to	relax	stresses,	easily	create	a	molecular	
contact	and	dissipate	energy	upon	debonding.	 Indeed,	PSAs	should	be	soft	and	relax	
stresses	 to	 favor	 the	 contact	 with	 the	 substrate	 [3],	 but	 they	 should	 also	 be	 highly	
dissipative	and	lightly	physically	or	chemically	crosslinked	to	resist	to	the	applied	stress	
once	 the	 bond	 is	 formed.	 From	 a	 technological	 point	 of	 view,	 the	 PSA	 matrix	 is	
characterized	by	tack,	peel	adhesion	and	resistance	to	shear.	Tack	is	the	property	that	
enables	an	adhesive	 to	 form	a	bond	with	 the	surface	of	another	material	upon	brief	
contact	and	under	 light	pressure;	peel	adhesion	 is	 the	 force	required	to	peel	away	a	
patch	 from	a	surface;	shear	adhesion	represents	 the	resistance	of	 the	matrix	 to	 flow	
over	long	times	and	moderate	loads	[4].		
The	literature	reports	the	feasibility	to	design	PSAs	able	to	deliver	several	drugs	made	
from	 a	 poly(ethylacrylate-co-methylmethacrylate-co-
trimethylammonioethylmethacrylate	chloride),	 traded	with	the	name	of	EudragitÒ	RL	
PO	 (EuRL)	 [5].	 However,	 no	 information	 is	 available	 about	 either	 the	 viscoelastic	
behavior	or	the	adhesive	properties	of	such	compositions.	
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This	study	focuses	on	the	evaluation	of	the	viscoelastic	and	adhesive	properties	of	PSAs	
made	of	EuRL	differently	plasticized	in	order	to	identify	a	matrix	suitable	to	develop	a	
patch	and	clarify	 the	possible	relationships	between	the	main	rheological	descriptors	
and	the	adhesive	properties	of	such	patch	and	the	drug	release	pattern.	This	kind	of	
relationship	is	rarely	investigated,	although	it	could	provide	useful	information	to	design	
both	 transdermal	 patches	 and	 medicated	 plasters	 in	 the	 attempt	 to	 optimize	 their	
performance.		
To	achieve	this	goal,	several	PSA	were	designed	by	mixing	EuRL	in	different	ratios	(40-
60%	w/w)	with	two	plasticizers,	namely	triacetin	(TRI)	and	tributyl	citrate	(TBC).	The	drug	
release	 properties	 of	 the	 optimal	 combinations	 were	 evaluated	 by	 adding	 three	
different	 drugs,	 namely	 ibuprofen,	 flurbiprofen	 and	 ketoprofen.	 PSAs	 were	
characterized	 in	 terms	 of	 rheological	 and	 tack	 properties.	 Probe	 tack	 tests	 were	
performed	 not	 only	 to	 evaluate	 the	 adhesive	 properties	 of	 the	 PSAs,	 but	mainly	 to	
understand	better	the	debonding	mechanisms	[6,7].	The	patches	were	characterized	by	
measuring	 shear	 and	 peel	 adhesion	 and	 cold	 flow,	 which	 refers	 to	 the	 dimensional	
change	and/or	deformation	of	the	polymeric	matrix	of	a	patch	beyond	the	boundaries	
[8].	The	drug	release	pattern	was	determined	by	both	in	vitro	dissolution	test	and	in	vitro	
skin	permeation	using	human	epidermis	as	membrane.			
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2.2	Materials	and	Methods	
2.2.1	Materials	
Poly(ethylacrylate-co-methylmethacrylate-co-trimethylammonioethylmethacrylate	
chloride),	traded	with	the	name	of	EudragitÒ	RL	PO	(EuRL),	with	molar	ratio	of	1:2:0.2	
and	molecular	weight	32	kDa,	was	kindly	donated	by	Rofarma	Italia	(Gaggiano,	 Italy).	
Tributyl	 citrate	 (Citroflex	 4,	 TBC)	 was	 supplied	 by	 Morflex	 (Greensboro,	 USA)	 and	
triacetin	 (TRI),	 ethyl	 acetate	 (EtOAc)	 and	 isopropanol	 (iPrOH)	 were	 purchased	 from	
Sigma	 Aldrich	 (Milan,	 Italy).	 The	 release	 liner	 used	 for	 patch	 preparation	 was	 a	
siliconized	polyester	film	from	Saint	Gobain	kindly	donated	by	Bouty	(Cassina	de	Pecchi,	
Italy),	while	the	backing	layer	was	a	polyester	film	with	a	thickness	of	57	µm	(Polifibra,	
Agrate	 Brianza,	 Italy).	 Three	 active	 ingredients	 were	 selected:	 S-ibuprofen	 (IB)	 was	
purchased	from	Dipharma	Francis	(Baranzate,	 Italy);	ketoprofen	(KP)	and	flurbiprofen	
(FP)	 from	 Farmalabor	 (Canosa	 di	 Puglia,	 Italy).	 All	 solvents	were	 of	 analytical	 grade,	
unless	specified.	
	
	
2.2.2	Blend	preparation		
To	obtain	the	EuRL	organic	dispersion,	the	powder	was	dispersed	in	the	solvent,	ethyl	
acetate	or	isopropanol,	at	the	concentration	of	40%	w/w.	The	polymeric	blends	were	
prepared	by	adding	the	plasticizer	(TBC	or	TRI)	to	the	EuRL	dispersions.	The	amount	of	
TBC	or	TRI	ranged	between	40	and	60%	with	respect	to	EuRL	weight.	When	the	active	
ingredient	(i.e.	IB,	KP	or	FP)	was	added	to	EuRL	mixture,	it	was	preliminarily	dissolved	in	
the	plasticizer	and,	then,	added	to	the	polymeric	dispersion.	The	drug	content	was	4%	
w/w	calculated	on	EuRL	weight.		
The	polymeric	dispersion	was	mixed	for	3	hours	at	60	°C	with	a	magnetic	stirrer	of	100	
rpm.	One	night	of	rest	was	necessary	in	order	to	reduce	the	air	bubbles	formed	during	
the	stirring	and	to	favor	the	full	swelling	of	the	polymeric	chains.		
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2.2.3	Rheological	properties	in	the	linear	regime	
The	rheological	characteristics	were	measured	on	a	Discovery	Hybrid	Instrument	HR-3	
(TA	 Instruments,	 New	 Castle,	 USA).	 The	 frequency-dependence	 of	 the	 viscoelastic	
moduli	G’	and	G’’	was	characterized	with	a	parallel	plate	geometry	(diameter	20	mm),	
by	using	a	crosshatched	upper	plate	for	the	formulations	containing	the	lower	amount	
of	plasticizer	and	a	sandblasted	plate	for	the	other	formulations.		
Sample	preparation.	In	order	to	obtain	equilibrated	samples	of	about	1	mm	thickness,	a	
special	sample	holder	was	used.	The	device	consisted	of	lower	plate	geometry,	to	which	
a	ring	was	fixed	through	a	Teflon	tape;	this	particular	device	allowed	to	put	10-15	mL	
(depending	on	the	plasticizer	concentration)	of	solution	and	completely	dry	 it	(slowly	
drying	 in	air	 for	48	hours,	and	then	30	minutes	of	drying	at	45	°C);	 the	same	sample	
holder	was	used	to	test	the	sample	on	the	rheometer	by	simply	removing	the	holding	
ring	just	before	the	analysis	(after	the	7	days	required	for	matrices	maturation).		
Experimental	setup.	To	evaluate	the	linear	viscoelastic	regime,	a	strain-sweep	procedure	
at	1	Hz	was	performed;	then,	a	 frequency-sweep	deformation	(0.01	-	100	rad/s)	was	
applied	to	the	sample	and	the	resulting	response	in	terms	of	stress	was	measured.	Each	
sample	was	analyzed	first	at	25	°C	and	then	at	32	°C.	The	analyses	were	performed	in	
triplicate	to	verify	the	reproducibility	of	the	experimental	conditions.		
	
	
2.2.4	ATR-FTIR	Spectroscopy	
Attenuated	 total	 reflectance	 Fourier	 transform	 infrared	 (ATR-FTIR)	 spectra	 were	
recorded	over	the	wavenumber	region	4000-650	cm-1	with	an	ATR-FTIR	spectrometer	
(Perkin	Elmer,	Waltham,	USA),	equipped	with	a	diamond	crystal.	For	each	sample	256	
scans	 were	 collected	 at	 a	 resolution	 of	 2	 cm-1.	 Spectra	 were	 ATR	 corrected	 and	
smoothed	and	then	analyzed	by	using	Origin	Pro	(Origin	Lab).	The	maximum	absorbance	
of	peaks	in	the	1650	and	1800	cm-1	region	was	assigned	by	second	derivate.	
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2.2.5	Differential	scanning	calorimetry	(DSC)	
The	glass	transition	temperature	(Tg)	of	EuRL/plasticizer	blends	was	evaluated	by	DSC	
(DSC1	Instrument,	Mettler-Toledo,	CH)	according	to	the	method	previously	described	
[9].	
	
	
2.2.6	Probe	tack	test	
Probe	 tack	 experiments	 were	 performed	 on	 a	 custom-designed	 probe	 apparatus	
adapted	on	a	MTS	810	hydraulic	testing	machine,	allowing	the	simultaneous	observation	
of	the	debonding	process	through	a	transparent	glass	substrate	[10].	
Sample	preparation.	In	order	to	get	films	of	thickness	180	-	200	µm	on	a	glass	slide		
2.6	´	10	´	0.2	cm3	previously	cleaned	and	activated	by	a	plasma	technique,	2	-	3	mL	
(depending	on	their	concentration)	of	each	placebo	formulation	were	deposited	on	each	
glass	slide	(using	a	perfectly	levelled	support	plate).	Each	sample	was	dried	slowly	in	air	
for	 48	 hours	 and	 then	 for	 30	 minutes	 in	 an	 oven	 at	 45	 °C.	 The	 PSA	 thickness	 was	
measured	by	a	white	light	scattering	technique	with	an	optical	profilometer	(Microsurf	
3D,	Fogale	nanotech,	Nimes,	France).	The	resulting	PSAs	were	stored	in	a	container	to	
prevent	dust	for	the	7	days	required	for	the	matrices	maturation	at	room	temperature.		
Experimental	setup.	The	experiments	were	carried	out	as	 follows:	a	 flat-ended	probe	
was	brought	into	contact	with	the	adhesive	layer	at	a	constant	probe	velocity	of	30	µm/s	
until	a	set	compression	force	was	reached,	kept	at	a	fixed	position	for	a	given	time	of	10	
s,	and	subsequently	removed	at	a	constant	crosshead	speed	which	was	varied	between	
1	and	1000	µm/s.	Experiments	were	conducted	at	room	(storage)	temperature	(25	±	0.5	
°C)	and	at	skin	surface	temperature	(32	±	0.5	°C).	The	probe	was	made	of	stainless	steel	
with	a	diameter	of	9.7	mm;	this	substrate	was	preferred	because	it	is	a	common	material	
with	a	simple	behavior.	Since	surface	roughness	can	affect	probe	test	results,	the	degree	
of	surface	roughness	was	well	controlled:	the	flat	end	of	the	probe	was	polished	with	
several	grades	of	abrasive	paper;	the	same	probe	was	used	throughout	a	series	of	tests	
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and	its	flat	end	was	cleaned	with	acetone.	The	applied	contact	forces	were	10,	40	and	
70	N	for	the	formulations	containing	60,	50	and	40%	w/w	of	plasticizer,	respectively.	
During	each	experiment,	the	force,	the	displacement	of	the	crosshead	and	the	time	were	
acquired	 simultaneously.	 Since	 the	 results	 are	 influenced	 by	 the	 film	 thickness,	 the	
force-distance	curve	was	converted	into	a	stress-strain	curve.		
The	 tensile	 stress	 (s)	 was	 calculated	 by	 dividing	 the	 force	 registered	 during	 the	
detachment	(F)	for	the	contact	area	(A),	evaluated	by	the	video	streaming,	as	follows:	
	! = 	$ %	 	 	 	 	 	 	 	 	 Eq.	2.1	
	
Defining	ℎ	as	being	the	time-dependent	thickness	of	the	adhesive	layer	and	ℎ'	as	the	
initial	adhesive	layer	thickness	the	nominal	strain	(e)	was	calculated	as	follows:	
	( = 	 ℎ − ℎ' ℎ'	 	 	 	 	 	 	 	 Eq.	2.2	
	
The	area	under	the	curve	recorded	by	the	instrument	software	was	defined	as	the	work	
of	separation	(W).	
Selected	images	from	recorded	films	were	digitized	and	analyzed.	Tests	were	carried	out	
on	the	selected	placebo	formulations	because	the	low	amount	of	drug	did	not	affect	the	
adhesive	 and	 debonding	 mechanisms	 of	 PSAs.	 Each	 formulation	 was	 analyzed	 in	
triplicate	to	verify	the	reproducibility	of	the	experimental	conditions.		
	
	
2.2.7	Preparation	of	transdermal	patches	
Patches	 were	 prepared	 by	 casting,	 using	 a	 laboratory-coating	 unit	 Mathis	 LTE-S(M)	
(Mathis,	Oberhasli,	CH),	equipped	with	a	blade	coater.	The	mixture	was	spread	on	the	
backing	layer.	The	coating	thickness	was	set	at	350	µm	in	order	to	obtain	a	dry	film	of	
about	50	-	100	µm.	The	spread	mixture	was	dried	at	60	°C	for	30	minutes	and	covered	
with	the	release	liner.	Finally,	patches	were	sealed	in	an	airtight	container	and	stored	at	
25	±	0.1	°C	over	a	7-day	period.		
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2.2.8	Thickness	of	the	matrices	of	the	transdermal	patches	
A	sample	of	2.5	cm	´	2.5	cm	of	the	patch	was	placed	between	the	jaws	of	the	MI	1000	
micrometer	 (ChemInstruments,	 Fairfield,	 USA).	 First,	 the	 whole	 thickness	 (TW)	 was	
measured;	 then,	 the	 respective	 thicknesses	 of	 both	 backing	 layer	 and	 release	 liner	
(TBL+RL)	were	measured.	
The	thickness	of	the	matrix	layer	was	calculated	as	TW	–	TBL+RL.	The	results	are	expressed	
as	the	mean	of	five	measurements.	
	
	
2.2.9	Shear	adhesion	
The	 shear	 adhesion	 was	 performed	 using	 an	 8	 Bank	 Oven	 Shear	 HT8	 Instrument	
(ChemInstruments,	Ichemico,	Cuggiono,	Italy).	
Sample	preparation.	Each	patch	sample	was	cut	in	order	to	obtain	specimens	of	25	mm	
´	60	mm	using	three	samples	from	each	formulation.	Each	specimen	was	placed	on	the	
test	panel	center;	 it	was	applied	to	cover	an	area	of	25	mm	´	25	mm	without	added	
pressure.	A	clamp	was	placed	on	the	masked	free	end	of	the	specimen	and	was	aligned	
in	order	to	ensure	a	uniform	distribution	of	the	load.		
Experimental	setup.	The	test	assembly	was	placed	in	the	test	stand	so	at	an	angle	of	2°	
from	vertical,	minimizing	the	peel	forces	that	eventually	acted	on	the	patch.	A	mass	of	
500	g	was	applied	 to	 the	 clamp	 [11].	 The	entire	 setup	was	enclosed	 in	a	 controlled-
temperature	 chamber	 in	 order	 to	maintain	 the	 specimens	 at	 32	 ±	 0.5	 °C.	 The	 time	
required	to	completely	detach	the	specimen	from	the	test	panel	was	recorded.	
The	results	are	expressed	as	the	mean	±	standard	deviation	of	three	specimens	for	each	
formulation.	
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2.2.10	Peel	adhesion	180°	test	
The	peel	adhesion	test	at	180°	measures	the	patch	adherence	when	peeled	at	a	180°	
angle	 from	 a	 standard	 steel	 or	 Teflon	 panel	 [12].	 The	 tests	were	 performed	 using	 a	
tensile	machine	equipped	with	a	50N	cell	 (Instron	5965,	 ITW	Test	and	Measurement	
Italia	S.r.l.,	Trezzano	sul	Naviglio,	Italy).	
Sample	preparation.	Each	patch	sample	was	cut	to	obtain	strips	of	12	mm	´ 	120	mm	and	
was	folded	about	5	mm	from	its	release	liner	and	a	tape	leader	was	placed	on	about	3	
mm	of	 the	exposed	patch	with	 the	adhesive	side	of	 the	 tape	attached	 to	 the	one	of	
patch.	The	remainder	of	the	tape	 leader	was,	then,	 folded	on	 itself	 to	form	a	double	
thickness	leader.	Then,	the	release	liner	was	removed	and	the	specimen	was	placed	onto	
the	Teflon	test	panel.	The	prepared	specimen	was	first	smoothed	with	a	2.04	kg	roller	
and	then	stored	in	an	airtight	container	at	25	±	0.1	°C	for	15	minutes.		
Experimental	setup.	The	specimen	was	placed	into	the	instrument	with	the	free	end	of	
the	tape	leader	being	placed	into	the	instrument	clamp	[11].	Six	specimens	were	pulled	
from	the	plate	at	a	180°	angle	at	a	peel	speed	of	300	mm/min.	
The	 average	 force	was	 calculated	 as	 the	 arithmetic	mean	 of	 all	 values	 of	 the	 linear	
portion	 of	 the	 curve.	 The	 peel	 values	 are	 expressed	 in	 centiNewton	 per	 centimeter	
(cN/cm)	 by	 dividing	 the	 registered	 force	 by	 the	 width	 of	 the	 patch.	 The	 results	 are	
expressed	as	the	mean	±	standard	deviation	of	six	specimens	for	each	formulation.	
	
	
2.2.11	Cold	flow	
The	 cold	 flow	was	 evaluated	 after	 a	 storage	 period	of	 one	month	 at	 40	±	 1	 °C.	 The	
dimensional	changes	in	punched-out	sample	were	measured	using	a	graph	paper.		
The	evaluation	was	performed	on	samples	punched	in	order	to	obtain	a	patch	of	32	mm	
diameter	covered	with	a	release	liner	of	40	mm	diameter.	The	samples,	sealed	in	single	
airtight	pocket,	were	stored	at	40	±	1	°C	for	one	month.	The	extent	of	cold	flow	was	
expressed	as	the	maximum	migration	of	the	adhesive	in	mm	on	the	release	liner	(Fig.	
2.1).	
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Figure	2.1	-	Schematic	representation	of	cold	flow	phenomenon.	
	
	
The	cold	flow	was	considered	negligible	if	the	PSA	was	not	visually	detectable	outside	
the	backing	layer.	The	analysis	was	performed	in	triplicate.	
	
	
2.2.12	Drug	content	
An	 exactly	 weighted	 2.54	 cm2	 patch	 sample	 was	 dissolved	 in	 20	 mL	 methanol	 by	
sonication	(UP200st,	Hielscher,	Teltow,	Germany)	and	mechanically	stirred.	Afterwards,	
the	 samples	were	 left	 at	 rest	 for	 three	 hours	 and	 diluted	with	 20	mL	mobile	 phase	
(described	below).	Each	value	represents	the	average	of	three	measurements.		
	
	
2.2.13	Dissolution	test	
The	dissolution	was	performed	by	using	an	apparatus	SR8	PLUS	dissolution	test	station	
(Hanson	 Research,	 Chatsworth,	 USA)	 according	 to	 “Dissolution	 test	 for	 transdermal	
patches”	of	European	Pharmacopoeia	9.1	(2017)	[13].	
A	patch	sample	of	8.0	cm2	was	placed	flat	on	the	disk	with	the	release	liner	surface	facing	
up.	The	backing	layer	was	attached	on	the	disk	by	using	a	cyanoacrylate	adhesive.	The	
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vessels	were	filled	with	300	mL	of	pH	7.4	PBS	buffer,	the	water	bath	temperature	was	
kept	at	32	±	0.5	°C	and	the	paddle	speed	was	set	at	25	rpm.	At	predetermined	intervals,	
5	mL	samples	were	collected	and	immediately	replenished	with	fresh	medium.		
The	solutions	were	assayed	by	HPLC,	according	to	the	methods	reported	below.	Each	
result	represents	the	average	of	three	determinations.		
The	release	rate	constant	was	calculated	according	to	the	Higuchi’s	equation	as	follows:	
	*+ *, =	-./'.1	 	 	 	 	 	 	 	 Eq.	2.3	
	
where	Mt	is	the	amount	of	drug	released	at	time	t,	M¥	is	the	drug	loading	in	the	matrix	
and	k	is	the	release	rate	constant	expressed	as	h-1.	
	
	
2.2.14	In	vitro	drug	permeation	
Skin	preparation.	The	permeation	studies	were	performed	using	abdominal	skin	from	
female	donors,	who	underwent	cosmetic	surgery	and	signed	an	informed	consent	for	
the	 use	 of	 biological	 samples	 for	 research	 purposes	 [14].	 After	 removing	 the	
subcutaneous	 fatty	 tissue,	 skin	 was	 kept	 frozen	 until	 further	 use.	 For	 the	 sample	
preparation,	adequate	pieces	of	the	frozen	skin	were	immersed	in	water	at	60	°C	for	60	
s,	 according	 to	 an	 internal	 protocol	 [15].	 After	 this	 treatment,	 the	 epidermis	 was	
carefully	removed	from	the	underlying	tissue	with	the	help	of	forceps.	The	integrity	of	
all	tissue	samples	was	assessed	measuring	their	electrical	resistance	(voltage:	100	mV,	
frequency:	100	Hz;	Agilent	4263B	LCR	Meter,	Microlease,	Cernusco	sul	Naviglio,	Italy),	
using	a	modified	Franz	diffusion	cell	 (PermeGear,	Hellertown,	USA)	with	an	effective	
penetration	area	and	a	receptor	volume	of	0.636	cm2	and	3	mL,	respectively.	Samples	
with	an	electrical	impedance	resistance	higher	than	30	kΩ·cm2	were	used	for	the	in	vitro	
permeation	experiments	[16].	
Experimental	 setup.	 The	 receiver	 compartment	of	 Franz	diffusion	 cell	was	 filled	with	
0.9%	w/v	NaCl	solution.	Patches	of	2.5	cm2	were	used	as	donor	phase	and	they	were	
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applied	with	slight	pressure	with	the	adhesive	layer	in	contact	with	the	stratum	corneum	
side	before	mounting	the	diffusion	cell.	
These	tissue	samples	were	sandwiched	between	the	donor	and	receptor	compartments	
of	the	diffusion	cell,	with	the	stratum	corneum	facing	up	the	donor	compartment.	The	
upper	and	lower	parts	of	the	vertical	Franz	cell	were	sealed	with	ParafilmÒ	and	fastened	
together	by	means	of	a	clamp.	The	system	was	kept	at	37	±	1	°C	by	means	of	a	circulating	
water	 bath	 so	 that	 the	 skin	 surface	 temperature	 was	 at	 32	 ±	 1 °C	 and	 the	 receiver	
medium	was	continuously	maintained	under	stirring	with	a	magnetic	bar.		
The	experiments	(three	replicates	per	formulation)	were	performed	over	a	24	h	period	
under	 occlusive	 conditions.	 During	 this	 period,	 200	 μL	 samples	 were	 drawn	 at	
predetermined	intervals	and	replaced	by	aliquots	of	the	receptor	fluid.	Sink	conditions	
were	maintained	throughout	the	experiment.	Samples	were	analyzed	by	HPLC	according	
to	the	methods	described	below.		
The	cumulative	amount	(Q)	permeated	through	the	skin	per	unit	of	area	was	calculated	
from	 the	 concentration	of	 each	 substance	 in	 the	 receiving	medium	and	plotted	as	 a	
function	of	time.	The	steady	flux	(J)	was	calculated	as	the	slope	of	the	linear	portion	of	
the	plot.	Finally,	the	efficiency	of	transdermal	patches	(E%)	in	drug	releasing	over	a	24	h	
period	was	calculated	as	the	ratio	between	the	Q24h	and	drug	content	per	cent.	
	
	
2.2.15	Drug	assay	
The	 drug	 concentration	 in	 each	 patch,	 in	 the	 dissolution	media	 and	 in	 the	 receiving	
media	 were	 quantified	 by	 HPLC	 analysis	 (Agilent	 HP	 1100,	 Chemstation,	 Hewlett	
Packard,	 Santa	Monica,	 USA).	 The	 following	 chromatographic	 conditions	were	 used:	
column:	HyperCloneTM	5µm	BDS	C18	130,	150	mm	´	4.6	mm	(Phenomenex,	Torrance,	
USA);	mobile	phase:	acetonitrile/water	pH	2.6	 (60/40,	%	v/v);	 flow	rate:	1.5	mL/min;	
wavelengths:	225	nm	(IB),	255	nm	(KP)	or	246	nm	(FP);	temperature:	25	°C;	 injection	
volume:	20	µL.	The	drug	concentrations	were	determined	from	standard	curves	in	the	
0.1	-	50.0	µg/mL	range.	
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2.2.16	Statistical	analyses	
The	performances	of	the	matrices	in	terms	of	drug	release	rates	were	compared	by	
analysis	of	the	variance	followed	by	Tukey	post-analyses	(Daniel’s	XL	Tollbox	6.70).	The	
level	of	significance	was	taken	as	p	<	0.05.	
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2.3	Results	and	Discussion	
2.3.1	Pressure	sensitive	adhesive	physico-chemical	characterization	
The	performances	of	a	PSA	are	related	to	its	ability	to	form	a	molecular	contact	with	the	
adherent,	 to	 its	 rheological	behavior	and,	obviously,	 to	 its	adhesive	properties.	All	of	
these	 characteristics	 are	 strongly	 dependent	 on	 the	 application	 temperature.	 It	 is	
generally	 recognized	 that	 when	 the	 glass	 transition	 temperature	 (Tg)	 of	 a	 lightly	
entangled	and	high	molecular	weight	polymer	is	25	-	45	°C	lower	than	the	application	
temperature	 the	material	 becomes	 sticky	 [17].	 Since	 the	 raw	 EuRL	 exhibited	 a	 Tg	 of	
about	63	 °C	 and	 the	 skin	 temperature	 is	 about	32	 °C,	 the	addition	of	 a	plasticizer	 is	
necessary.	Among	the	widely	used	plasticizers	of	poly(methyl	methacrylate)	derivatives,	
TBC	and	TRI	were	selected	and	in	both	the	cases	a	minimum	amount	of	40%	w/w	of	TBC	
and	TRI	was	necessary	to	reach	the	target	Tg	value	(i.e.	Tg	<	0	°C).	Indeed,	the	Tg	values	
of	the	EuRL	plasticized	with	TBC	and	TRI	at	40%	w/w	resulted	-20	±	1	°C	and	-7	±	5	°C,	
respectively.	On	the	basis	of	these	data,	the	effect	of	the	plasticizer	on	the	rheological	
and	adhesive	performances	of	EuRL	was	studied	in	the	40-60%	w/w	range.	
The	 rheological	analyses	 revealed	 that,	with	 the	exception	of	 form.	no.	6,	 showing	a	
distinctly	liquid	behavior	in	the	considered	frequency	range,	all	the	formulations	were	
viscoelastic:	 at	 low	 frequency	 the	 viscous	modulus	 (G’’)	 was	 higher	 than	 the	 elastic	
modulus	 (G’);	while	at	high	 frequency	G’	dominated	and	a	clear	crossover	point	was	
visible	at	25	°C	(the	patterns	are	exemplifies	in	Fig.	2.2).		
	
Chapter	2	
	
	
58	
	
Figure	2.2	-	Evolution	of	G’	(solid	line)	and	G’’	(dashed	line)	as	a	
function	of	frequency.	(a)	Form.	no.	6	at	25	°C	and	(b)	form.	no.	4	
at	25°C.	
	
	
The	influence	of	each	variable	on	the	rheological	behavior	of	a	PSA	can	be	clarified	by	
evaluating	 the	 vertical	 shift	 in	 elastic	 and	 viscous	 moduli,	 i.e.	 G’	 and	 G’’,	 and	 the	
horizontal	shift	of	the	crossover	point.		
In	order	to	evaluate	the	structure	of	the	PSA	in	the	in-use	conditions,	the	experiments	
were	 also	 performed	 at	 32	 °C.	 As	 expected,	 even	 if	 each	 formulation	maintained	 its	
rheological	character,	 increasing	the	temperature	from	25	°C	to	32	°C	the	elastic	and	
viscous	moduli	decreased	(Tab.	2.1)	and	the	relaxation	time	(23),	defined	by	1 5	at	the	
crossover	point	between	the	storage	(G’)	and	viscous	(G’’)	moduli,	decreased	according	
to	an	increase	of	the	fluidity	of	the	system.
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Table	2.1	–	Elastic	m
odulus	(G’)	as	a	function	of	frequency	and	tem
perature,	relaxation	tim
e	(!" )	and	G’	at	1	Hz	as	function	of	
tem
perature	and	adhesive	properties	(shear	and	peel	adhesion)	of	placebo	form
ulations.	
Form
.	
nos	
Solvent	
EuRL	
TBC	
TRI	
G’	(kPa)	
#$ 	(s)	
G’	(M
Pa)	
Shear	
adhesion	
(m
in)	
Peel	
adhesion	
(cN/cm
)	
0.05	rad/s	
100	rad/s	
1	Hz	
25	°C	
32	°C	
25	°C	
32	°C	
25	°C	
32	°C	
25	°C	
32	°C	
32	°C	
25	°C	
1	
EtO
Ac	
60	
40	
-	
22.98	
14.19	
618.47	
470.61	
26.31	
11.11	
1.86	x	10
-1	
1.46	x	10
-1	
1004.9	±	9.5	
14.1	±	8.0	
2	
EtO
Ac	
50	
50	
-	
4.39	
2.39	
177.91	
140.20	
3.22	
1.14	
5.70	x	10
-2	
4.32	x	10
-2	
18.2	±	3.5	
7.5	±	2.1	
3	
EtO
Ac	
40	
60	
-	
0.59	
0.27	
43.00	
35.56	
0.45	
0.16	
1.25	x	10
-2	
8.59	x	10
-3	
2.1	±	0.1	
3.2	±	0.5	
4	
EtO
Ac	
60	
-	
40	
4.98	
1.99	
330.02	
239.26	
0.81	
0.31	
9.90	x	10
-2	
6.72	x	10
-2	
869.6	±	12.4	
29.1	±	5.6	
5	
EtO
Ac	
50	
-	
50	
0.44	
0.12	
116.09	
84.09	
0.13	
0.05	
2.92	x	10
-2	
1.83	x	10
-2	
12.4	±	2.1	
17.6	±	3.7	
6	
EtO
Ac	
40	
-	
60	
- a	
5.97	x	10
-3	
33.20	
26.55	
0.01	
- b	
5.57	x	10
-3	
3.69	x	10
-3	
0.6	±	0.4	
15.0	±	1.7	
7	
iPrO
H	
60	
40	
-	
3.87	
1.90	
279.51	
192.31	
0.26	
0.12	
7.37	x	10
-2	
4.93	x	10
-2	
542.1	±	13.8	
8.4	±	2.4	
8	
iPrO
H	
60	
-	
40	
1.61	
0.58	
216.84	
138.53	
0.18	
0.08	
5.75	x	10
-2	
3.38	x	10
-2	
393.0	±	5.1	
17.8	±	0.7	
a:	not	determ
ined;	
b:	out	of	range.
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The	increasing	of	the	relative	amount	of	each	plasticizer	(from	40	to	60%	w/w)	caused	
shifts	in	the	elastic	and	viscous	moduli	at	each	frequency	(Tab.	2.1).	
Figure	 2.3a	 shows	 the	 rheological	 results	 obtained	 by	 analyzing	 the	 formulations	
containing	different	amounts	of	TBC	(form.	nos.	1,	2	and	3)	at	25	°C.		
	
	
	
Figure	2.3	-	Evolution	of	G’	(solid	line)	and	G’’	(dashed	line)	as	a	function	of	frequency.	(a)	
formulations	containing	TBC	and	(b)	formulations	containing	TRI.	(black	line:	formulations	
containing	40%	w/w	of	plasticizer,	grey	line:	formulations	containing	50%	w/w	of	plasticizer	
and	light	grey	line:	formulations	containing	60%	w/w	of	plasticizer).	Tests	were	performed	at	
25	°C.	
	
	
Even	 if	 all	 these	 formulations	 are	 viscoelastic	 fluids,	 the	 PSAs	 become	 more	 fluid	
increasing	the	plasticizer	amount.	Indeed,	the	observed	relaxation	time	decreased	when	
increasing	the	amount	of	TBC	(Tab.	2.1).		
Moreover,	TRI	appeared	a	better	plasticizer	of	EuRL	than	TBC.	Indeed,	it	was	clear	by	
frequency	 sweep	measurements	 at	 25	 °C	 that	 formulations	 containing	 TRI	 are	more	
liquid,	 showing	 higher	 terminal	 relaxation	 times	 (Fig.	 2.3b	 and	Tab.	 2.1).	 As	 already	
stated	above,	at	the	highest	concentration	of	plasticizer,	the	PSA	containing	TRI	showed	
a	liquid	behavior,	while	the	PSA	containing	TBC	at	the	same	concentration	behaved	as	a	
viscoelastic	material.	
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This	effect	cannot	be	merely	ascribed	to	the	differences	in	miscibility	of	TBC	or	TRI	with	
EuRL.	Indeed,	the	solubility	parameters	(∂),	calculated	for	these	plasticizers	(∂TBC	=	18.86	
MPa1/2;	∂TRI	=	20.82	MPa1/2)	and	for	EuRL	(∂EuRL	=	21.24	MPa1/2)	according	to	the	Fedors	
method	[18],	resulted	almost	superimposable.	Thus,	the	different	effects	of	the	selected	
plasticizers	on	the	EuRL	rheological	behavior	can	only	be	attributed	to	different	specific	
interactions.	The	comparison	of	ATR-FTIR	spectra	recorded	on	the	raw	materials	and	
different	PSAs	showed	significant	modifications	in	the	1800-1650	cm-1	region	attributed	
to	the	stretching	of	the	carbonyl	moieties	of	the	copolymer	and	plasticizers	(in	Fig.	2.4	
the	whole	spectra	are	reported).		
	
	
	
Figure	2.4	-	ATR-FTIR	spectra	of	raw	materials	(EuRL,	TBC	and	TRI)	and	formulations	containing	
50%	w/w	of	both	the	plasticizers.	
	
	
In	 this	 region,	 independently	 of	 the	PSA	 composition,	 the	 intensity	 of	 the	C=O	band	
decreased	 with	 respect	 to	 that	 registered	 on	 raw	 materials,	 suggesting	 a	 possible	
interaction	between	EuRL	and	the	two	plasticizers	mediated	by	H-bonds.	This	reduction	
of	the	carbonyl	peak	intensity	was	accompanied	by	a	significant	shift	of	the	band	toward	
higher	wavenumbers	(Fig.	2.5a	and	b).		
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Figure	2.5	-	ATR-FTIR	spectra	of	C=O	bands	of	the	raw	materials	and	formulations	1-6	in	the	
1650-1800	cm-1	region.	
	
	
Shifts	to	higher	wavenumbers	associated	with	lower	intensities	of	C=O	stretching	bands	
can	be	related	to	the	formation	of	novel	H-bonds	which	determines	changes	in	electron	
densities	on	different	atoms	[19].	Since	these	events	are	more	evident	 in	the	spectra	
registered	on	PSA	made	of	EuRL-TRI	(Fig.	2.5b)	than	on	those	made	of	EuRL-TBC	(Fig.	
2.5a),	it	is	reasonable	to	hypothesize	that	TRI	interacted	with	EuRL	more	strongly	than	
TBC,	in	agreement	with	the	higher	plasticizing	effect	verified	in	the	rheological	studies.		
Focusing	 now	 on	 the	 adhesion	 properties,	 it	 should	 be	 considered	 that	 the	 initial	
bonding	of	a	PSA	on	an	irregular	surface,	like	the	skin,	is	driven	by	the	wettability	and	
flow	properties	at	low	frequencies.	Moreover,	Dahlquist	suggested	that	a	sufficient	level	
of	adhesion	is	reached	when	the	PSA	exhibits	an	elastic	shear	modulus	lower	than	0.1	
MPa	measured	at	1	Hz	frequency	[20].	As	shown	in	Table	2.1,	all	the	formulations	fulfill	
the	 so-called	 Dahlquist	 criterion	 of	 tackiness	with	 the	 only	 exception	 of	 form.	 no.	 1	
showing	a	slightly	higher,	but	still	acceptable,	G’	value	either	at	room	temperature	and	
skin	temperature.	
The	performances	of	 the	designed	 formulations	were,	 then,	 further	characterized	by	
studying	the	debonding	mechanism	during	the	tack	tests.	
The	compression	force	to	apply	during	the	experiment	was	preliminary	evaluated	for	
each	sample	(performing	different	tests	at	different	contact	forces)	in	order	to	maintain	
constant	 the	 indentation	 of	 the	 probe	 in	 the	 adhesive	 layer	 (maximum	 15	 µm);	 the	
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objective	was	to	impose	a	contact	force	that	causes	an	indentation	that	did	not	influence	
the	shape	of	the	stress-strain	curve.		
Generally	 speaking,	 detachment	 patterns	 in	 probe	 tests	 are	mainly	 governed	 by	 the	
extent	of	plasticizer	in	the	formulation.	Figure	2.6a	exemplifies	the	typical	stress-strain	
curve	observed	for	the	formulations	with	the	lowest	plasticizer	concentration.		
	
	
Figure	2.6	-	Typical	stress-strain	curves,	schematic	and	video	captures	of	the	debonding	
mechanism	at	10	µm/s	and	25	°C	of	(a)	formulation	no.	8	and	(b)	6.	
	
	
The	detachment	pattern	shows	an	initial	cavitation	occurring	at	the	interface	between	
the	probe	and	the	PSA;	the	deformation	of	the	layer	during	the	debonding	process	was	
low	with	mainly	 lateral	 propagation	 and	 coalescence	 of	 the	 initial	 cavities	 along	 the	
interface	and	a	decrease	in	nominal	stress.		
This	mechanism	of	debonding	and,	therefore,	the	shape	of	the	stress-strain	curves	were	
not	influenced	much	by	changing	the	type	of	plasticizer	(form.	no.	7	vs	form.	no.	8)	or	
the	solvent	used	for	the	preparation	of	the	PSA	(form.	no.	7	vs	form.	no.	1	and	form.	no.	
4	vs	form.	no.	8)	as	shown	in	Fig.	2.7.		
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Figure	2.7	-	Stress-strain	curves	of	the	formulations	with	(a)	40%	w/w	of	plasticizer	and	
ethyl	acetate	as	solvent	(black	line:	TBC,	grey	line:	TRI);	(b)	40%	w/w	of	plasticizer	and	
isopropanol	as	solvent	(black	line:	TBC,	grey	line:	TRI);	(c)	40%	w/w	of	TBC	(black	line:	
ethyl	acetate,	grey	line:	isopropanol)	and	(d)	40%	w/w	of	TRI	(black	line:	ethyl	acetate,	
grey	line:	isopropanol).	Tests	were	performed	at	100	µm/s	and	32	°C.	Note	that	negative	
slopes	in	the	loading	part	of	the	curve	are	due	to	an	overcorrection	of	the	compliance	of	
the	machine,	but	do	not	affect	the	measured	adhesion	energy	(integral	under	the	
curve).	
	
	
Increasing	 the	 debonding	 rate,	 independently	 of	 the	 temperature,	 the	 maximum	
nominal	stress	and	the	work	of	adhesion	increased	significantly	(Fig.	2.8a	and	b),	at	least	
up	 to	 the	 values	 taken	 into	 consideration.	 This	 behavior	 can	 be	 attributed	 to	 the	
viscoelastic	 losses	 occurring	 in	 the	 adhesive	 layer,	 which	 increase	 with	 increasing	
deformation	rate.		
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Figure	2.8	-	Effect	of	the	debonding	velocity	(a	and	b)	and	of	the	plasticizer	amount	(c	and	d)	
on	the	stress-strain	curves.	Formulation	no.	7	tested	at	(a)	25	°C	and	(b)	32	°C.	(Light	grey	line:	
1000	µm/s,	grey	line:	100	µm/s,	black	line:	10	µm/s.).	Formulations	containing	(c)	TBC	and	(d)	
TRI.	(Black	line:	formulations	with	40%	w/w	of	plasticizer,	grey	line:	formulations	with	50%	
w/w	of	plasticizer,	light	grey	line:	formulations	with	60%	w/w	of	plasticizer.)	
	
	
In	order	to	evaluate	the	behavior	of	each	PSA	in	the	in-use	conditions,	experiments	were	
also	performed	at	32	°C.	No	significant	modifications	in	the	adhesive	and	detachment	
properties	were	observed.	
Increasing	the	amount	of	both	the	plasticizers	from	40%	w/w	to	60%	w/w,	the	maximum	
stress	decreased,	while	the	maximum	nominal	strain	increased	(Fig.	2.8c	and	d).	These	
trends	 were	 observed	 for	 all	 the	 tested	 debonding	 velocities,	 in	 each	 experimental	
condition.		
Keeping	constant	the	EuRL/plasticizer	ratio	at	40/60	w/w,	the	two	formulations	showed	
the	same	detachment	pattern	and	very	similar	stress-strain	curves	(Fig.	2.6b),	even	if	
they	 presented	 somewhat	 different	 rheological	 properties.	 Indeed,	 the	 debonding	
process	 was	 governed	 by	 a	 viscous	 flow,	 independently	 of	 the	 debonding	 rate	 and	
temperature.	 Four	 different	 stages	 were	 identified:	 (i)	 homogeneous	 deformation	
corresponding	 to	 a	 rapid	 increase	 of	 the	 force	 and	 no	 optically	 visible	 voids;	 (ii)	
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nucleation	 and	 rapid	 growth	 of	 voids	 at	 the	 probe-film	 interface,	 close	 to	 the	 point	
where	the	nominal	stress	goes	through	a	maximum;	(iii)	slow	growth	of	these	voids	until	
they	 occupy	most	 of	 the	 initial	 contact	 area;	 (iv)	 air	 penetration	 into	 the	 voids	 and	
breakage	 of	 the	 bonds	 with	 the	 formation	 of	 isolated	 fibrils	 that	 eventually	 break	
(cohesive	failure).		
It	 is	 interesting	to	note	that	both	the	formulations	containing	50%	w/w	of	plasticizer	
showed	the	first	type	of	debonding	mechanism	at	the	higher	debonding	velocities	(100	
and	1000	µm/s);	while	at	10	µm/s	they	presented	the	second	pattern,	even	if	no	residues	
were	optically	visible	at	the	end	of	the	experiments.	This	feature	may	be	attributed	to	
the	fact	that	at	lower	debonding	velocity	the	polymeric	chains	have	time	to	re-organize	
and	the	PSA	has	time	to	relax.	
	
	
2.3.2	Characterization	of	placebo	patches	
The	results	on	the	shear	adhesion	are	shown	in	Table	2.1.	They	represent	the	resistance	
of	the	matrix	to	flow	[21].	The	shear	adhesion	test	measures	the	ability	of	a	patch	to	
adhere	to	a	standard	steel	panel	under	a	constant	shear	stress.	Since	the	detachment	of	
the	patch	 from	 the	 stainless	 steel	 surface	occurred	 cohesively,	 the	data	obtained	by	
shear	adhesion	test	can	be	considered	as	a	true	measure	of	the	cohesive	strength	of	the	
PSA.	The	increase	in	plasticizer	content	caused	a	reduction	in	shear	adhesion	values,	due	
to	the	dilution	of	the	entanglements	of	the	polymer,	resulting	in	a	flowing	matrix.	This	
effect	appeared	clearly	with	both	the	plasticizers,	in	agreement	with	the	pattern	found	
in	the	rheological	measurements	at	0.05	rad/s	(Tab.	2.1).	However,	excluding	form.	no.	
6,	all	shear	adhesion	values	could	be	considered	suitable	for	the	development	of	a	patch	
intended	for	drug	administration	[22].		
The	 comparison	of	 the	 shear	 adhesion	values	also	 revealed	 that	 the	 solvent	used	 to	
prepare	the	formulation	had	an	impact	on	the	creep	resistance	of	placebo	formulations,	
since	the	patches	prepared	in	isopropanol	showed	lower	shear	adhesion	values	(form.	
nos	7	and	8,	Tab.	2.1)	relative	to	those	prepared	in	ethyl	acetate,	in	agreement	with	the	
rheological	studies.		
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Shifting	from	shear	adhesion	to	peel	adhesion,	that	represents	the	force	required	to	peel	
away	a	patch	from	a	substrate,	it	is	noteworthy	that	only	the	patches	prepared	with	the	
highest	amount	of	plasticizer	left	residues	on	the	stainless	steel	panel,	confirming	the	
low	cohesive	properties	of	the	formulation.	Consequently,	in	order	to	compare	all	the	
formulations,	the	experiments	were	repeated	using	a	TeflonÒ	panel	which	presents	a	
lower	critical	surface	tension	[23].	In	presence	of	TRI,	the	peel	adhesion	values	appeared	
slightly	higher	than	those	of	the	corresponding	patches	prepared	with	TBC	(Tab.	2.1).	In	
both	 cases,	 the	 peel	 adhesion	 values	 decreased	 with	 increasing	 the	 plasticizer	
concentration.	However,	the	relatively	low	peel	force	values	obtained	can	be	considered	
satisfactory,	 since	 higher	 values	 could	 cause	 pain	 or	 skin	 damage	 upon	 the	 patch	
removal.		
Cold	 flow,	 a	 phenomenon	 similar	 to	 drug	 leakage	 from	 the	 edge	 of	 membrane-
controlled	patch,	is	one	of	the	possible	product	quality	defects	[24].	It	represents	the	
migration	of	 the	PSA	outside	 the	edge	of	 the	backing	 layer	during	 the	storage	and	 it	
occurs	when	the	matrix	flows	like	a	very	viscous	liquid	between	the	backing	layer	and	
the	release	liner	during	the	storage.	As	an	example,	this	negative	effect	may	result	in	a	
patch	 stuck	 to	 the	 primary	 packaging	 container	 becoming	 unusable.	 Both	 the	
formulations	containing	60%	w/w	of	plasticizer	presented	cold	flow	after	one	month	of	
storage	at	40	°C,	in	agreement	with	the	rheological	data	and	independently	of	the	type	
of	plasticizer;	while	this	phenomenon	was	absent	when	40-50%	w/w	of	plasticizer	was	
used.	These	results	on	placebo	patches	are	consistent	with	the	data	reported	by	Lin	and	
co-workers	 [25]	who	reported	that	the	minimum	amount	of	TRI	and	TBC	required	to	
obtain	 a	 positive	 answer	 to	 the	 rolling	 ball	 tack	 test	 was	 about	 35%	 and	 40%,	
respectively.	 Similarly,	 40%	 of	 di-butyl-phthalate	 was	 required.	 Indeed,	 when	 this	
plasticizer	was	used	at	lower	concentrations	(i.e.	30%	and	20%)	to	develop	transdermal	
patches	 containing	 risperidone	 [26]	 and	 verapamil	 [27],	 it	 would	 not	 be	 enough	 to	
conferee	suitable	adhesive	properties	to	the	patch.	Indeed,	since	the	patch	was	fixed	to	
animal	 skin,	probably,	 the	 rheological	and	adhesive	properties	were	not	 sufficient	 to	
guarantee	the	residence	of	the	patch	on	application	site	over	the	required	time	period.	
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2.3.3	Characterization	of	the	drug-loaded	patches	
Since	the	drugs	loaded	polymeric	mixtures	prepared	by	using	ethyl	acetate	shrunk	after	
casting	 on	 the	 release	 liner,	 the	 drug	 loaded	 patches	 were	 prepared	 using	 only	
isopropanol	as	solvent.	In	all	cases,	the	drug	content	complied	the	Ph.	Eur	assay	for	the	
uniformity	of	dosage	units	(Tab.	2.3).	
The	 loading	of	 the	selected	active	 ingredients,	namely	 IB,	KP	and	FP,	 to	 the	matrices	
containing	TRI	did	not	significantly	influenced	the	debonding	patterns	(data	not	shown),	
peel	 adhesion	 and	 shear	 adhesion	 values	 (Tables	 2.1	 and	 2.2).	 These	 data	 were	 in	
agreement	with	the	lack	of	modification	on	the	rheological	pattern	suggesting	that	the	
loaded	 drug	 did	 not	 modify	 the	 interactions	 occurring	 between	 EuRL	 and	 TRI.	
Conversely,	 in	 the	 case	of	 the	 adhesive	matrices	 prepared	using	 TBC,	 a	 reduction	of	
about	20%	shear	adhesion	values	was	found	(Tables	2.1	and	2.2)	probably	because	of	a	
plasticizing	effect	exerted	by	the	loaded	drugs	(Tables	2.1	and	2.2).	It	can	be	assumed	
that	the	drug	can	disrupt	the	interactions	occurring	between	TBC	and	EuRL	in	favor	of	
the	formation	of	H-bonds	between	the	carboxylate	of	the	drug	and	the	ester	moieties	
of	the	copolymer	[12,29].	
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Table	2.2	–	Elastic	m
odulus	(G’)	as	a	function	of	frequency	and	tem
perature,	relaxation	tim
e	(!" )	as	a	function	of	
tem
perature	and	adhesive	properties	(shear	and	peel	adhesion)	of	drug-loaded	form
ulations.	
Form
.	
nos	
Solvent	
EuRL	
TBC	
TRI	
Drug	
G’	(kPa)	
#$ 	(s)	
Shear	
adhesion	
(m
in)	
Peel	adhesion	
(cN/cm
)	
0.05	rad/s	
100	rad/s	
25	°C	
32	°C	
25	°C	
32	°C	
25	°C	
32	°C	
32	°C	
25	°C	
9	
iPrO
H	
60	
40	
-	
IB	
2.85	
1.37	
244.96	
182.75	
0.25	
0.10	
433.0	±	5.3	
8.9	±	0.2	
10	
iPrO
H	
60	
40	
-	
KP	
1.03	
0.53	
157.85	
128.21	
0.20	
0.07	
420.8	±	1.6	
5.2	±	2.5	
11	
iPrO
H	
60	
40	
-	
FP	
1.97	
0.79	
215.90	
134.22	
0.23	
0.08	
430.1	±	0.6	
8.8	±	3.1	
12	
iPrO
H	
60	
-	
40	
IB	
1.16	
0.49	
157.85	
117.64	
0.17	
0.07	
385.7	±	5.4	
12.2	±	0.8	
13	
iPrO
H	
60	
-	
40	
KP	
0.90	
0.33	
160.91	
117.86	
0.13	
0.05	
388.2	±	1.0	
36.4	±	2.1	
14	
iPrO
H	
60	
-	
40	
FP	
1.34	
0.53	
188.61	
142.71	
0.16	
0.07	
380.6	±	2.1	
9.8	±	0.4	
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Table	2.3	–	Drug	content,	drug	release	constants	and	m
ain	param
eters	calculated	from
	in	vitro	skin	perm
eation	
experim
ents	(drug	flux,	i.e.	J;	cum
ulative	drug	am
ount	perm
eated,	i.e.	Q
24h ;	efficiency	of	transderm
al	patches,	
E%
)	of	drug-loaded	patches.	
Form
.	
nos	
Solvent	
EuRL	
TBC	
TRI	
Drug	
Drug	content	
(µg/cm
2)	
k	
(h
-0.5)	
J	
(µg/cm
2/h)	
Q
24h	
(µg/cm
2)	
E%
	
(%
)	
9	
iPrO
H	
60	
40	
-	
IB	
153.0	±	4.2	
0.58	±	0.04	
2.35	±	0.41	
51.26	±	7.42	
33.5	±	4.8	
10	
iPrO
H	
60	
40	
-	
KP	
159.9	±	3.8	
0.57	±	0.01	
0.45	±	0.22	
24.14	±	4.10	
15.1	±	2.6	
11	
iPrO
H	
60	
40	
-	
FP	
120.4	±	5.1	
0.38	±	0.03	
1.63	±	0.17	
29.57	±	11.32	
24.6	±	9.4	
12	
iPrO
H	
60	
-	
40	
IB	
131.3	±	4.3	
0.67	±	0.01	
-*	
-*	
-*	
13	
iPrO
H	
60	
-	
40	
KP	
171.5	±	10.9	
0.78	±	0.01	
-*	
-*	
-*	
14	
iPrO
H	
60	
-	
40	
FP	
130.8	±	14.7	
0.51	±	0.07	
-*	
-*	
-*	
*:	not	determ
ined.
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The	lack	of	significant	differences	due	to	the	loaded	drug	can	be	justified	on	the	bases	
of	the	solubility	parameters.	Indeed,	all	the	three	compounds	can	be	considered	freely	
mixable	with	 EuRL	 being	 their	 values	 (IB:	 20.91	MPa1/2;	 KP:	 23.23	MPa1/2;	 FP:	 21.53	
MPa1/2)	close	to	that	of	the	placebo	adhesive	matrix	(EuRL/TBC	60/40:	20.28	MPa1/2).		
Since	the	therapeutic	performances	of	a	transdermal	patch	are	affected	not	only	by	its	
adhesive	properties,	which	assure	the	residence	time	of	the	drug	on	the	skin	surface,	
but	also	by	the	ability	of	the	patch	itself	to	release	the	drug,	both	the	in	vitro	drug	release	
and	in	vitro	drug	skin	permeation	were	determined.		
Table	2.3	shows	the	drug	release	constants	calculated	according	to	the	Higuchi	model.		
These	data	were	in	agreement	with	the	rheological	results	on	the	effect	of	the	type	of	
plasticizer.	The	patches	containing	TRI	presented	significantly	higher	release	constants	
(p	<	0.05)	due	to	the	more	pronounced	plasticizing	effect:	the	 lower	the	G’	values	at	
each	 frequency	and,	more	 important,	 the	shorter	 the	relaxation	time,	 the	higher	 the	
viscous	characteristic	of	the	PSA	at	a	given	temperature	and	the	faster	the	release	rate	
(Tables	2.2	and	2.3).	Hence,	the	presence	of	TRI	increased	the	mobility	of	the	polymeric	
chains	favoring	the	diffusion	of	the	drug	through	the	matrix.	
The	in	vitro	drug	release	can	be	considered	satisfactory	for	all	formulations	since	it	was	
almost	complete	within	7	hours	independently	of	the	plasticizer	type	(Fig.	2.9a).	Thus,	
the	plasticizer	was	selected	only	on	the	bases	of	the	adhesive	properties	and,	therefore,	
the	 in	vitro	skin	permeation	studies	were	carried	out	on	formulations	containing	TBC	
(Fig.	2.9b).	
	
	
Figure	2.9	-	In	vitro	release	profile	(a)	from	TBC	patches	and	in	vitro	drug	permeation	profiles	
through	human	skin	(b)	of	the	tested	transdermal	patches.	(Solid	line:	IB,	Dashed	line:	KP,	and	
Dot-dashed	line:	FP).	
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PSA	 made	 of	 EuRL	 and	 TBC	 in	 the	 60/40	 w/w	 ratio	 allowed	 to	 obtain	 a	 prolonged	
permeation	profile	of	the	loaded	drug	over	least	24	h.	Moreover,	it	should	be	underlined	
that	the	efficiency	of	transdermal	patches	in	drug	releasing	over	a	24	h	period	(E%,	Tab.	
2.3)	resulted	almost	double	with	respect	to	commercially	available	plasters	containing	
flurbiprofen	 (Transactâ)	and	 ibuprofen	 (Ibupasâ)	and	slightly	 lower	with	 respect	 that	
loaded	with	ketoprofen	(Keplatâ)	[11].		
The	increased	mobility	(or	lower	viscosity)	caused	by	the	selected	drugs	did	not	have	a	
significant	 influence	 on	 the	 permeation	 process.	 Indeed,	 the	 tR	 values	 taken	 as	
representative	of	the	rheological	pattern,	did	not	match	with	the	drug	fluxes	through	
the	skin,	suggesting	that	the	barrier	properties	of	the	stratum	corneum	ruled	the	skin	
permeation	process.	In	other	words,	drug	permeation	pattern	after	the	application	of	a	
patch	on	the	skin	is	governed	by	different	mechanisms	[30]	with	respect	to	the	in	vitro	
drug	release.	In	particular,	the	flux	determined	for	KP	was	about	5-fold	lower	than	FP	
and	IB,	which	were	not	statistically	different	(p	>	0.05).	The	same	trend	was	found	by	
Swart	and	coauthors	[31]	using	aqueous	saturated	solution	as	the	reported	KP	flux	was	
about	 4-fold	 lower	 than	 those	measured	 in	 the	 case	 of	 FP	 and	 IB,	 which	 were	 not	
significantly	 different.	 Hence,	 the	 overall	 data	 suggested	 that	 the	 skin	 permeation	
process	was	not	influenced	by	the	formulation	in	a	PSA	made	of	EuRL	and	TBC,	but	only	
by	the	physico-chemical	characteristics	of	the	loaded	drug,	which	dictates	the	diffusion	
process	through	the	stratum	corneum.	
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2.4	Conclusions	
The	 current	work	 allowed	defining	 the	 rheological	 and	 adhesive	properties	 of	 highly	
plasticized	 EuRL.	 The	 results	 permitted	 to	 identify	 the	 optimal	 copolymer/plasticizer	
ratio	 and	 evidenced	 the	 relevance	 of	 the	 PSA	 rheological	 behavior	 on	 the	 adhesive	
properties,	reflecting	on	debonding	pattern	and	shear	adhesion.	In	the	specific	case	of	
EuRL,	the	optimal	polymer/plasticizer	ratio	was	in	the	60/40-50/50%	w/w	range	for	both	
TBC	and	TRI.	The	selected	drugs	loaded	at	4%	w/w	decreased	the	relaxation	time,	as	an	
indication	of	the	increase	of	the	matrix	fluidity.	This	behavior	has	a	beneficial	impact	on	
the	in	vitro	release,	determined	by	dissolution	test:	the	shorter	the	relaxation	time,	the	
higher	the	drug	release	rate.	
In	 conclusion,	 the	knowledge	of	 viscoelastic	properties	of	 the	PSA	appears	 crucial	 to	
identify	the	formulation	space	during	the	development	of	transdermal	patches	and/or	
medicated	 plasters	 and	 to	 optimize	 their	 performances.	 In	 particular,	 the	 matrix	
relaxation	time	appears	a	suitable	parameter	to	optimize	the	copolymer/plasticizer	ratio	
and	establish	the	possible	influence	of	the	active	ingredient.	
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SEBS	block	copolymers	as	novel	
materials	to	design	transdermal	
patches	
	
		
	
Abstract	
Background:	Styrene-block-(ethylene-co-butylene)-block-styrene	(SEBS)	copolymers	are	
biocompatible	elastomers	with	outstanding	stability	to	UV	radiations.	This	work	aimed	
to	design	a	pressure	sensitive	adhesive	made	of	SEBS	to	demonstrate	the	potentialities	
of	such	class	of	materials	in	the	design	of	transdermal	patches.		
Research	design	and	methods:	The	influence	of	SEBS	and	tackifier	molecular	weights	on	
rheological	pattern,	debonding	mechanisms,	 technological	properties	 (i.e.	 tack,	 shear	
and	peel	adhesion)	as	well	as	on	the	in	vitro	biopharmaceutical	performances	(i.e.	drug	
release	and	skin	permeability)	was	investigated	using	ibuprofen	and	nicotine	as	model	
drugs.	
Results:	Relationships	among	the	rheological	pattern	and	the	main	technological	and	in	
vitro	biopharmaceutical	properties	of	the	prepared	patches	were	evidenced.	The	higher	
the	liquid	component	of	the	matrix,	the	lower	its	cohesiveness	and	the	faster	the	drug	
release	rate.	The	drug	itself	can	affect	the	rheological	pattern	of	the	matrix,	influencing	
the	whole	patch	performances.		
Conclusions:	SEBS	copolymers	are	suitable	materials	to	design	drug	in-adhesive	patches.	
SEBS-low	 molecular	 weight	 is	 the	 polymer	 worthy	 of	 consideration	 because	 of	 its	
favorable	 viscoelastic	 behavior.	 The	 in	 vitro	 drug	 permeability	 of	 ibuprofen	was	 not	
limited	by	the	polymeric	matrix	if	compared	to	the	commercial	reference	product.	
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3.1	Introduction	
Styrene	block	copolymers	are	common	thermoplastic	elastomers.	They	consist	of	two	
polystyrene	 endblocks,	 which	 give	 characteristics	 of	 rigidity,	 and	 a	 linear	 midblock,	
which	 confers	 flexibility	 to	 the	 copolymer.	 Thus,	 they	 combine	 the	 mechanical	
properties	of	rubbers	with	the	processability	characteristics	of	thermoplastics.		
Among	these	copolymers,	styrene-isoprene-styrene	(SIS)	copolymers	were	studied	for	
the	 design	 of	 pressure	 sensitive	 adhesives	 [1]	 suitable	 for	 the	 preparation	 of	 both	
transdermal	patches	[2]	and	medical	devices	[3].	However,	because	of	their	chemical	
structure,	they	need	to	be	compounded	with	relatively	large	amount	of	antioxidants	to	
improve	 their	 stability	 [4].	 Conversely,	 styrene-block-(ethylene-co-butylene)-block-
styrene	 (SEBS)	 copolymers,	 being	 hydrogenated	 derivatives,	 are	 elastomers	 with	
outstanding	stability	to	UV	radiations	and	well-known	biocompatibility	[5,6].		
The	 compounding	 of	 SEBS	with	 paraffin	 oil	 and	 aliphatic	 resins	 (tackifiers)	 allows	 to	
obtain	 a	 hot	melt	 pressure	 sensitive	 adhesive	with	 a	 very	 high	 creep	 resistance	 [7].	
Tackifiers	are	crucial	components	in	reducing	the	polymer	glass	transition	temperature	
and	elastic	modulus,	that	generally	is	too	high	at	room	temperature	to	form	a	bond	upon	
simple	contact	[8].		
Taking	 into	 account	 all	 these	 considerations,	 SEBS	 copolymers	 appear	 potential	
candidates	 for	 the	 design	 of	 transdermal	 patches	 and/or	 medicated	 plasters.	
Nevertheless,	the	performances	of	the	system	obtained	by	casting	technique	is	scantly	
investigated	and	the	ability	of	the	compounded	pressure	sensitive	adhesive	to	release	a	
loaded	drug	unknown.		
The	aim	of	this	work	was	to	design	a	pressure	sensitive	adhesive	made	SEBS	in	order	to	
demonstrate	 the	 potentialities	 of	 such	 class	 of	 materials	 in	 the	 development	 of	
transdermal	patches.		
The	 adhesive	 properties	 were	 conferred	 using	 low	molecular	 weight,	 but	 high	 glass	
transition	temperature	hydrocarbon	resin	as	tackifier	and	liquid	paraffin	as	plasticizer	
[9].	In	particular,	two	resins,	with	similar	ring	and	ball	softening	point,	cloud	point	and	
glass	 transition	 temperature,	 but	 different	 molecular	 weight	 were	 selected.	 The	
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designed	pressure-sensitive	adhesives	(PSA)	were	prepared	by	using	SEBS	with	different	
average	molecular	weight	 and	 characterized	 by	 determining	 rheological	 pattern	 and	
adhesive	 properties	 focusing	 the	 attention	 on	 debonding	 behavior	 under	 different	
operative	 conditions.	 The	 in	 vitro	 biopharmaceutical	 performances	 of	 patches	 were	
assessed	using	ibuprofen	and	nicotine,	as	model	drugs.	These	compounds	were	selected	
in	 order	 to	 explore	 the	 impact	 of	 loading	 cationic	 and	 anionic	 compounds	 on	 the	
designed	hydrophobic	matrices.	
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3.2	Materials	and	Methods	
3.2.1	Materials	
SEBS	are	available	on	market	under	the	trade	name	of	Europrene	SOL	THÒ.	Three	types	
of	SEBS	were	kindly	gifted	by	Versalis	SpA	(San	Donato	Milanese,	Italy):	Europrene	SOL	
THÒ	2311	(three	blocks,	30%	bound	styrene,	average	molecular	weight	45.61	kDa,	SEBS-
L),	 Europrene	 SOL	 THÒ	 2312	 (three	 blocks,	 30%	 bound	 styrene,	 average	 molecular	
weight	 64.23	 kDa,	 SEBS-M),	 and	Europrene	 SOL	THÒ	 2315	 (three	blocks,	 32%	bound	
styrene,	average	molecular	weight	176.35	kDa,	SEBS-H).	 In	order	to	make	the	system	
adhesive	it	was	necessary	to	add	a	tackifier.	The	hydrocarbon	resins	RegaliteÔ	R1100	
(ring	and	ball	softening	point	=	100	°C,	glass	transition	temperature	=	50	°C,	cloud	point	
=	78	°C,	molecular	weight	=	850	g/mol)	and	EastotacÔ	H100W	(ring	and	ball	softening	
point	 =	 100	 °C,	 glass	 transition	 temperature	 =	 41	 °C,	 cloud	point	 =	 81	 °C,	molecular	
weight	=	1000	g/mol)	were	received	from	Eingemann&Veronelli	Spa	(Rho,	Italy).	Paraffin	
oil	was	obtained	by	Carlo	Erba	(Milan,	Italy).	In	order	to	produce	transdermal	patches	a	
polyester	 film	 was	 chosen	 as	 backing	 layer,	 while	 a	 polyester	 siliconized	 film	 Saint	
Gobain	 (thickness	 120	 µm)	 as	 release	 liner.	 S-ibuprofen	 (IB)	 and	 nicotine	 (NT)	were	
purchased	 from	Dipharma	Francis	 (Baranzate,	 Italy)	 and	 Sigma–Aldrich	 (Milan,	 Italy),	
respectively.	 Toluene	was	 chosen	 as	 solvent	 and	 it	 was	 purchased	 by	 Sigma	 Aldrich	
(Milan,	Italy).	All	the	solvents	were	of	analytical	grade.	
 
 
3.2.2	Mixture	preparation	
SEBS	were	swelled	 in	 toluene	and	 the	mixtures	were	continuously	maintained	under	
stirring	 with	 a	 magnetic	 bar	 at	 room	 temperature	 for	 1	 hour.	 Then,	 the	 other	
components	 of	 the	 formulation	 were	 added	 and	 the	 mixture	 was	 continuously	
maintained	under	stirring	with	a	magnetic	bar	at	room	temperature	for	23	hours.	When	
the	drug-loaded	 formulations	were	prepared,	 IB	 or	NT	were	 added	 in	 the	polymeric	
mixture,	before	adding	tackifier	and	oil.	To	prepare	PSAs	and	patches	24	hours	were	
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waited	in	order	to	reduce	air	bubbles	formed	during	the	stirring.	A	pre-formulation	study	
was	 performed	 to	 achieve	 the	 final	 compositions	 of	 the	 formulations,	 which	 are	
illustrated	in	Table	3.1.
			  
Table	3.1	-	Placebo	and	drug-loaded	form
ulation	com
positions	(%
,	w
/w
)	
Form
.	
code	
SEBS-L	
SEBS-M
	
SEBS-H	
Regalite
Ò	
H1100	
Eastotak
Ò
	
H100W
	
Paraffin	
oil	
IB	
NT	
1	
10	
-	
-	
40	
-	
50	
-	
-	
2	
10	
-	
-	
-	
40	
50	
-	
-	
3	
-	
10	
-	
40	
-	
50	
-	
-	
4	
-	
10	
-	
-	
40	
50	
-	
-	
5	
-	
-	
10	
40	
-	
50	
-	
-	
6	
-	
-	
10	
-	
40	
50	
-	
-	
7	
9	
-	
-	
36	
-	
45	
10	
-	
8	
9	
-	
-	
-	
36	
45	
10	
-	
9	
-	
9	
-	
36	
-	
45	
10	
-	
10	
-	
9	
-	
-	
36	
45	
10	
-	
11	
-	
-	
9	
36	
-	
45	
10	
-	
12	
-	
-	
9	
-	
36	
45	
10	
-	
13	
9.7	
-	
-	
-	
38.8	
48.5	
-	
3	
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3.2.3	Rheological	properties	in	the	linear	regime	
The	rheological	parameters	were	determined	on	a	Discovery	Hybrid	 Instrument	HR-3	
(TA	Instruments),	by	using	a	parallel	crosshatched	plate	geometry	(diameter:	22	mm).	
In	order	to	obtain	equilibrated	samples	of	about	2	mm	of	thickness,	a	special	sample	
holder	(6	´	5	cm)	made	of	teflon	was	used.	This	device	allows	to	put	the	solution	and	
completely	dry	the	sample.	A	2-steps	drying	process	was	used:	firstly,	PSAs	were	dried	
under	a	glass	cover	for	24	hours	at	room	temperature	and	subsequently	in	an	oven	at	
45	 °C	 under	 vacuum	 for	 24	hours.	 After	 7	 days,	 necessary	 for	 PSA	maturation,	 each	
sample	was	cut	(diameter:	22	mm)	by	using	a	punch.	Strain	sweep	measurements	were	
performed	at	6.28	rad/s	 (1	Hz)	 in	order	to	define	the	 linear	viscoelastic	region	(LVR).	
Once	the	LVR	was	set,	a	frequency	sweep	deformation	in	the	range	10-2	–	102	rad/s	was	
applied	into	the	sample.	The	strain	value	was	in	the	LVR.	Each	sample	was	analyzed	first	
at	25	°C	and	then	at	32	°C.	Storage	modulus	(G’),	loss	modulus	(G’’)	and	phase	angle	(∂)	
were	used	to	characterize	the	samples.	Each	experiment	was	performed	twice	to	test	
data	reproducibility.	
 
 
3.2.4	Texture	analysis	
In	order	to	obtain	a	dry	PSA	of	180	–	200	µm	thickness,	3	mL	of	polymeric	mixture	was	
deposited	on	a	standard	glass	slide	(2.6	´ 	10	´ 	0.2	cm3),	previously	cleaned	and	activated	
by	a	plasma	technique.	A	2-steps	drying	process	was	used:	firstly,	PSAs	were	dried	under	
a	glass	cover	for	24	hours	at	room	temperature	and	subsequently	in	an	oven	at	45	°C	
under	 vacuum	 for	 24	 hours.	 The	 PSA	 final	 thickness	was	 evaluated	 by	 a	white	 light	
scattering	 technique	 with	 an	 optical	 profilometer	 (Microsurf	 3D,	 Fogale	 nanotech).	
Probe	tack	experiments	were	performed	on	a	custom-designed	apparatus	adapted	on	a	
MTS	 810	 hydraulic	 testing	 machine,	 allowing	 the	 simultaneous	 observation	 of	 the	
debonding	 process	 through	 a	 transparent	 glass	 substrate	 [10].	 A	 circular	 flat	 ended	
probe	was	brought	into	contact	with	the	PSA	layer	at	a	constant	velocity	(30	µm/s).	Once	
the	probe	and	the	sample	came	into	contact,	a	compressive	force	of	30	N	was	applied.	
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The	 probe	was	maintained	 in	 contact	with	 the	 adhesive	 for	 10	 s.	 At	 the	 end	 of	 the	
contact	time,	the	probe	was	separated	from	the	adhesive	by	retracting	it	at	a	predefined	
speed,	namely	10,	100	and	1000	µm/s.	The	probe	was	made	of	stainless	steel	with	a	
diameter	of	9.7	mm.	The	probe	flatness	was	well-controlled	by	polishing	it	with	several	
grades	of	abrasive	paper.	The	entire	probe	tack	set-up	was	enclosed	 in	a	controlled-
temperature	chamber	to	perform	the	experiments	at	room	temperature	(25	±	0.5	°C)	
and	 at	 skin	 surface	 temperature	 (32	 ±	 0.5	 °C).	 The	 whole	 force-distance	 curve	 was	
recorded.	 The	 detachment	 force	 and	 the	 elongation	 at	 break	 were	 measured	 and	
expressed	 in	 Newton	 (N)	 and	 millimetres	 (mm),	 respectively.	 Since	 the	 results	 are	
influenced	by	the	PSA	thickness,	the	force-distance	curve	was	converted	into	a	stress-
strain	curve.	The	tensile	stress	(s)	and	the	strain	(e)	were	calculated	according	to	the	
following	equations:	
	! = 	$ %	 	 	 	 	 	 	 	 	 Eq.	3.1	
	& = 	 ℎ − ℎ) ℎ)	 	 	 	 	 	 	 	 Eq.	3.2	
		
The	term	F	is	the	force	registered	during	the	detachment,	A	is	the	probe	surface	area,	
that	was	exactly	determined	by	the	video	streaming,	h(t)	is	the	PSA	elongation	at	time	t	
and	 h0	 is	 the	 PSA	 initial	 thickness.	 To	 evaluate	 the	 fracture	 occurring	 during	 the	
debonding	process	all	tests	were	filmed	and	recorded	through	a	45°	mirror.	For	each	
formulation	and	for	each	experimental	condition	three	tests	were	carried	out.	
 
 
3.2.5	Patches	preparation	
Patches	 were	 prepared	 by	 casting,	 using	 a	 laboratory-coating	 unit	 Mathis	 LTE-S(M)	
(Mathis,	CH),	equipped	with	a	doctor	knife.	Coating	thickness	was	set	at	250	µm	in	order	
to	obtain	a	dry	matrix	of	about	50	µm.	The	mixture	was	spread	on	the	backing	layer,	
dried	at	40	°C	for	20	minutes	and	covered	with	the	release	liner.	To	evaluate	the	final	
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matrix	 thickness	 a	MI	 1000	micrometer	 (ChemInstrument,	USA)	was	 used.	 	 Samples	
were	sealed	in	a	well-closed	airtight	container	and	stored	at	25	±	0.1	°C	until	use.		
 
 
3.2.6	Inclined	ball-tack	test	
The	inclined	ball	tack	test	allows	quantifying	the	ability	of	a	patch	to	quickly	adhere	to	a	
stainless	steel	surface.	In	this	test,	balls	characterized	by	different	diameters	are	rolled	
on	the	adhesive	surface	of	a	patch	placed	onto	an	inclined	rump;	the	largest	ball	that	
stops	 on	 the	 patch	 determines	 the	 tack	 value.	 According	 to	 the	 “Inclined	 ball	 tack	
testing”	reported	in	the	Japanese	Pharmacopeia	XVII	(JP),	a	plane	having	an	inclination	
angle	of	30°	was	used.	Samples	were	cut	in	order	to	obtain	specimen	larger	than	10	mm	
in	width	and	70	mm	in	length.	Each	specimen	was	fixed	in	the	prescribed	position	on	the	
ramp	with	the	adhesive	layer	side	up.	The	upper	and	the	lower	ends	of	the	specimen	
were	covered	with	proper	shits	of	paper,	leaving	50	mm	of	adhesive	free	at	the	central	
position.	The	balls	must	be	able	to	roll	down	without	slipping.	Several	hard	steel	balls	
(from	no.	2	to	no.	32,	 JP	XVII)	were	used.	The	higher	the	ball	number,	the	 larger	the	
diameter	and,	therefore,	the	greater	the	weight.		Before	running,	each	ball	was	cleaned	
by	rinsing	it	with	acetone	and	wiping	dry	with	absorbent	cleaning	material	followed	by	
air	drying	for	at	least	10	min.	Finally,	each	ball	was	rolled	over	the	inclined	plane	from	
the	top	of	the	ramp	onto	the	adhesive	tape.	Specimens	were	changed	for	each	run.	The	
number	(No.)	of	the	largest	ball	that	stops	on	the	adhesive	represents	the	value	of	the	
inclined	ball	tack	test.	The	assay	was	performed	in	triplicate.	
	
 
3.2.7	Shear	adhesion	
Shear	adhesion	tests	were	performed	by	using	an	8	Bank	Oven	Shear	HT8	Instrument	
(ChemInstruments,	Ichemico,	Cuggiono,	Italy),	in	accordance	with	an	internal	method	
described	by	Cilurzo	et	al.	[11].	The	adhesive	sample	was	pressed	onto	the	stainless	steel	
test	panel	with	a	bonding	area	of	2.5	´	2.5	cm2	by	a	double	pass	of	a	2.04	kg	roller.	A	
Chapter	3	
	
	
88	
mass	of	500	g	was	hung	at	the	end	of	each	sample.	To	perform	tests	at	32	°C	a	controlled-
temperature	chamber	was	used.	Each	result,	namely	the	time	required	to	completely	
detach	the	sample	from	the	test	panel,	is	expressed	as	the	mean	±	standard	deviation	
of	six	determinations	for	each	formulation.	
	
 
3.2.8	Peel	adhesion	180°	test	
Peel	adhesion	measures	the	patch	adherence	when	peeled	at	180°	angle	to	a	standard	
steel	panel.	Peel	strength	was	measured	on	a	tensile	machine	equipped	with	a	50	N	cell	
(Instron	5965,	 ITW	Test	and	Measurement	 Italia	S.r.l.,	 Trezzano	 sul	Naviglio,	 Italy)	at	
room	temperature.	Tests	were	performed	according	to	an	internal	method	[11].	
Six	samples	for	each	formulation	were	run	by	using	a	stainless	steel	panel,	a	peel	angle	
of	180°	and	peel	speed	of	300	mm/min.	
The	average	force	was	calculated	as	the	arithmetical	mean	of	the	values	of	the	linear	
portion	of	the	curve.	The	peel	values	are	expressed	in	cN	per	centimeter	width	of	the	
adhesive	patch	under	test.	The	results	are	expressed	as	the	mean	±	standard	deviation	
of	six	determinations	for	each	formulation.	
 
 
3.2.9	Cold	flow	
Cold	 flow	 represents	 the	migration	of	 the	PSA	outside	 the	edge	of	 the	backing	 layer	
during	the	storage	and	involves	drug	 leakage	from	the	edge	of	membrane-controlled	
patch.	It	occurs	if	the	matrix	flows	like	a	very	viscous	liquid	between	the	backing	layer	
and	the	release	liner	during	the	storage	[12].	Circular	samples	(PSA	and	backing	layer)	
were	cut	by	using	a	punch	(diameter:	32	mm),	maintaining	the	whole	release	liner.	After	
one	month	of	storage	in	a	sealed	container	impervious	to	water	and	humidity	at	40	±	1	
°C,	samples	were	evaluated	in	terms	of	migration	of	the	PSA	on	the	release	liner.	The	
dimensional	changes	were	measured	using	a	graph	paper	and	cold	flow	was	considered	
negligible	if	the	PSA	was	not	visually	detectable	outside	the	backing	layer.		
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The	analyses	were	performed	in	triplicate.	
	
	
3.2.10	Drug	content	
To	determine	 IB	or	NT	amount	 loaded	 in	 the	patches,	a	 specimen	of	2.54	cm2,	after	
release	liner	removing,	was	firstly	weighed	and	then	dissolved	in	50	mL	of	methanol.	To	
support	the	complete	solubilization	of	the	adhesive	matrix	and	the	active	principle,	the	
sample	was	sonicated	for	1	hour	and	then	left	at	rest	overnight.	The	solution	was	filtered	
through	a	0.45	µm	polypropylene	filter	(VWR	International,	Milan,	Italy),	diluted	with	
mobile	phase	(1:9	v/v)	and	assayed	by	HPLC,	according	to	the	methods	reported	below.	
Each	value	represents	the	average	of	three	determinations	for	each	formulation.		
 
 
3.2.11	Dissolution	test	
The	IB	or	NT	release	rate	was	studied	by	using	an	apparatus	SR8	PLUS	Dissolution	test	
station	(Hanson	Research,	CA,	USA)	according	to	the	“Dissolution	test	for	transdermal	
patches”	of	European	Pharmacopoeia	9.2	(2017)	[13].	
A	sample	of	8.04	cm2	was	cut	and	placed	flat	on	a	disk	with	the	release	liner	surface	
facing	up.	The	backing	layer	was	attached	on	the	disk	by	using	a	cyanoacrylate	adhesive	
and	the	release	liner	was	removed.	Each	vessel	was	filled	with	300	mL	of	PBS	buffer	(pH	
7.4),	the	water	bath	temperature	was	maintained	at	32	±	0.5	°C	and	the	paddle	speed	
was	 set	 at	 25	 rpm.	 Samples	 (5	 mL)	 were	 collected	 at	 predetermined	 intervals	 and	
assayed	 by	HPLC,	 according	 to	 the	methods	 reported	 in	 paragraph	 3.2.13.	 An	 equal	
volume	of	fresh	medium	was	immediately	added	to	maintain	the	dissolution	volume.		
The	release	rate	constant	was	calculated	according	to	Higuchi’s	equation	as	follows:	
	*+ *, =	-./).1	 	 	 	 	 	 	 	 Eq.	3.3	
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where	Mt	is	the	amount	of	drug	released	at	time	t,	M¥	is	the	drug	loading	in	the	matrix	
and	k	is	the	release	rate	constant	expressed	as	h-1.	Each	value	represents	the	average	of	
three	determinations.		
	
 
3.2.12	In	vitro	skin	permeation		
Since	pig	ear	skin	shows	similar	histological	and	physiological	characteristics	and	close	
permeability	properties	with	the	respect	to	human	skin	[14,15],	it	was	selected	to	study	
IB-permeation	 profile	 from	 SEBS-patches.	 The	 skin	 was	 obtained	 from	 the	 ears	 of	
different	pigs,	which	were	kindly	provided	by	a	local	slaughterhouse	(Milan,	Italy).		
The	pig	ear	skin	was	separated	from	the	underlying	cartilage,	cut	into	squares	of	about	
3.5	 cm2	 and	 sealed	 in	 evacuated	 plastic	 bags	 and	 frozen	 at	 -20	 °C.	 Before	 the	
experiments,	the	samples	were	equilibrated	at	room	temperature	for	1	hour.		
The	 integrity	of	 all	 tissue	 samples	was	 assessed	measuring	 their	 electrical	 resistance	
(voltage:	100	mV,	frequency:	100	Hz;	Agilent	4263B	LCR	Meter,	Microlease,	Cernusco	
sul	Naviglio,	Italy)	[16].		
The	permeation	experiments	were	performed	using	modified	Franz	cell	under	occlusive	
conditions.	They	have	a	diffusion	area	of	0.636	cm2	and	a	receptor	compartment	volume	
of	approximately	5	mL.	This	compartment	was	filled	with	physiological	solution.	Patch	
sample	(2.54	cm2)	was	applied	onto	pig-ear	with	slight	pressure.	The	patch-skin	system	
was	carefully	mounted	on	the	lower	part	of	the	Franz	cell	with	the	patch	facing	upward.	
The	upper	and	 lower	parts	of	 the	 vertical	 Franz	 cell	were	 sealed	with	ParafilmÒ	 and	
fastened	together	by	means	of	a	clamp.	The	system	was	kept	at	37	±	1	°C	by	means	of	a	
circulating	water	bath	so	that	the	skin	surface	temperature	was	at	32	±	1 °C	and	the	
receiver	medium	was	continuously	maintained	under	stirring	with	a	magnetic	bar.	At	
predetermined	interval	times	(1,	3,	5,	7	and	24	hours)	200	µL	samples	were	withdrawn	
from	the	receptor	compartment	and	an	equivalent	volume	of	 fresh	receiver	medium	
was	added.	Sink	conditions	were	maintained	throughout	the	experiment.	Samples	were	
analyzed	by	HPLC	according	to	the	method	described	below.		
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The	 cumulative	 amount	 permeated	 through	 the	 pig	 ear	 skin	 per	 unit	 of	 area	 was	
calculated	 from	 the	 concentration	 of	 IB	 in	 the	 receiving	 medium	 and	 plotted	 as	 a	
function	 of	 time.	 The	main	 calculated	 permeation	 parameters	 were	 the	 sum	 of	 the	
amount	of	drug	permeated	through	the	skin	(Q24h),	expressed	as	µg/cm2,	and	the	steady	
flux	(J),	expressed	as	µg/cm2/h	and	determined	as	the	slope	of	the	linear	portion	of	the	
plot.	The	results	of	each	permeation	experiments	are	expressed	as	the	mean	±	standard	
deviation	of	three	replicates	for	each	formulation.   
 
 
3.2.13	Drug	assay	
The	 IB	 and	 NT	 concentrations	 were	 quantified	 by	 HPLC	 analysis	 (Agilent	 HP	 1100,	
Chemstation,	Hewlett	Packard,	 Santa	Monica,	USA).	Regarding	 IB,	 20	µL	 sample	was	
injected	at	25	°C	on	a	HyperCloneTM	5µm	BDS	C18	130,	150	mm	x	4.6	mm	(Phenomenex,	
Torrance,	CA)	column.	The	composition	of	the	mobile	phase	was	acetonitrile/water	pH	
2.6	(60/40,	%	v/v).	The	flow	rate	was	1.5	mL/min.	The	wavelength	was	set	at	230	nm.	IB	
concentration	was	determined	from	a	standard	calibration	curves	in	the	0.1-50	µg/mL	
range.	
The	concentrations	of	NT	in	the	medium	were	determined	injecting	20	µL	sample	at	25	
°C	 on	 a	 C18	 reverse-phase	 column	 (Lichrospher,	 100	 RP-18E,	 Agilent,	 G).	 The	
composition	of	the	eluent	was	2.31	g/L	sodium	dodecyl	sulphate	in	acetonitrile/	13.6	
g/L	 potassium	dihydrogen	 phosphate	 solution	 (25/75,	%	 v/v).	 The	 flow	 rate	was	 1.5	
mL/min.	The	wavelength	was	set	at	254	nm.	The	drug	concentration	was	determined	
from	NT	standard	calibration	curves	ranging	between	0.1	and	50	µg/mL.	
	
	
3.2.14	Statistical	analyses	
The	performances	of	the	patches	in	terms	of	drug	release	rates	and	adhesive	properties	
were	compared	by	analyses	of	the	variance	followed	by	Tukey	post-analyses	(Daniel’s	
XL	Tollbox	6.70).	The	level	of	significance	was	taken	as	p	<	0.05.	
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3.3	Results	and	Discussion	
3.3.1	Pressure	sensitive	adhesive	characterization	
Rheological	oscillatory	tests	were	performed	to	assess	the	PSA	viscoelasticity.		
The	 rheological	measurements	 showed	 as	 the	materials	made	of	 SEBS-L	 behaved	 as	
viscoelastic	 fluids	over	the	whole	range	of	 frequencies,	while	the	others	prepared	by	
SEBS-M	and	SEBS-H	behaved	like	moderately	viscoelastic	solids.	As	shown	in	Figure	3.1,	
only	for	the	form.	no.	1,	the	elastic	modulus	decreased	strongly	at	low	frequency,	typical	
trend	of	a	material	with	a	pronounced	viscoelastic	character.	Therefore,	only	 for	this	
formulation	 the	 relaxation	 time	 (defined	as	 the	phase	angle	 inverse	at	 the	crossover	
point	 between	 the	 storage	 and	 viscous	 moduli)	 fell	 within	 the	 considered	 range	 of	
frequencies	and	resulted	0.40	and	0.13	second	at	25	and	32	 °C,	 respectively.	On	 the	
contrary,	the	storage	moduli	of	the	formulations	nos.	3	and	5	were	significantly	higher	
than	 the	 loss	modulus,	 confirming	 the	prevalence	of	 the	elastic	 component	over	 the	
viscous	one.		
 
 
 
Figure	3.1	-	Evolution	of	G’	with	frequency.	Tests	were	performed	at	25	°C	(Grey	line:	form.	no.	
1,	black	line:	form.	no.	3,	light	grey	line:	form.	no.	5).	
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The	storage	 (elastic)	moduli	at	0.1	 rad/s	and	25	°C	of	 the	 formulations	composed	by	
SEBS-M	or	SEBS-H	(form.	nos.	3	and	5)	were	closed	to	6	kPa	(Tab.	3.2).	The	formulation	
prepared	 by	 SEBS-L	 showed	 significant	 lower	 G’	 values	 at	 the	 same	 frequency	 and	
temperature	(about	0.5	kPa).	The	non-significant	difference	among	the	formulations	nos	
3	and	5	(Tab.	3.2),	despite	the	polymer	molecular	weight	was	different,	is	due	to	their	
elastic	behavior.	 Indeed,	 the	effect	of	 the	polymer	molecular	weight	 is	 relevant	only	
when	the	material	behaves	like	a	liquid.			
 
 
Table	3.2	-	Elastic	(storage)	moduli	at	0.1	rad/s	and	1	Hz.	
Form.	code	 Polymer	 Tackifier	
G’	(kPa)	 G’	(MPa)	
0.1	rad/s	 1	Hz	
1	 SEBS-L	 RegaliteÒ	H1100	 0.51	 2.11	x	10-3	
3	 SEBS-M	 RegaliteÒ	H1100	 5.94	 6.35	x	10-3	
5	 SEBS-H	 RegaliteÒ	H1100	 6.26	 6.54	x	10-3	
 
 
In	 order	 to	 develop	 suitable	 transdermal	 patches,	 the	matrix	 viscoelasticity	 plays	 an	
important	role	to	assure	the	appropriate	balance	among	cohesion,	to	avoid	a	too	high	
creep	 compliance	 and	obtain	 an	 adequate	 shear	 adhesion,	 to	dissipate	 energy	upon	
patch	application	and	obtain	a	suitable	peel	adhesion	during	the	removal	of	the	patch	
from	 the	 skin	 [17].	 In	 other	words,	 pressure	 sensitive	 adhesive	 should	behave	 as	 an	
elastic	 solid	 to	 guarantee	 a	 good	 resistance	 to	 shear	 over	 long	 times	 and,	 when	
subjected	to	the	peeling	process,	it	should	exhibit	a	viscous	pattern	to	dissipate	energy	
[18].	PSA	should	have	a	low	elastic	modulus	(G’)	value	at	low	frequencies	and	a	high	G’	
value	at	high	frequencies,	since	the	bonding	process	usually	undergoes	at	low	shear	rate	
and	the	peeling	process	undergoes	at	high	shear	rate	[19].	
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However,	 as	 shown	 in	 Table	 3.2,	 all	 the	 formulations	 satisfied	 Dahlquist’s	 criterion,	
according	 to	 which	 a	 good	 PSA	 has	 to	 show	 an	 elastic	 modulus	 determined	 at	 the	
bonding	frequencies	(1	Hz)	lower	than	0.1	MPa	[20].		
No	differences	on	the	rheological	pattern	were	observed	by	changing	the	tackifier.	On	
the	contrary,	increasing	temperature	from	room	to	application	temperature	of	32	°C,	G’	
and	G’’	decreased	as	the	viscoelastic	PSA	(form.	no.	1)	was	considered,	while	taking	into	
account	the	elastic	PSAs	(form.	nos.	3	and	5)	no	differences	were	noticed.	
	
Texture	experiments	were	performed	not	only	 to	 evaluate	 the	PSA	 instant	 adhesion	
properties,	but	also	its	debonding	mechanism.		
The	compression	force	(30	N)	applied	during	the	experiment	was	preliminary	evaluated	
and	 chosen,	 after	 performing	 different	 tests	 at	 different	 contact	 force,	 to	 be	 large	
enough	to	obtain	a	full	contact	between	the	PSA	and	the	probe	surface,	while	avoiding	
a	probe	indentation	higher	than	15	µm,	which	can	influence	the	results.	
There	was	no	relationship	between	the	maximum	stress	values	measured	during	the	
texture	tests	at	10,	100	and	1000	µm/s	debonding	velocity	and	the	elastic	moduli	of	the	
formulations	measured	at	a	frequency	ranging	between	0.01-100	rad/s	in	the	LVR.	The	
most	important	results	shown	in	Figure	3.2	concern	the	increase	in	the	maximum	strain	
and	 adhesion	 energy	 with	 the	 SEBS	 molecular	 weight.	 Figure	 3.2	 refers	 to	 the	
formulations	 prepared	with	 EastotacÔ	 H100W	 for	 sake	 of	 clarity	 since	 the	 selected	
tackifing	 resins	 did	 not	 affect	 PSA	 characteristics	 neither	 in	 terms	 of	 adhesive	 nor	
debonding	properties.	
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Figure	3.2	–	Effect	of	SEBS-molecular	weight	on	the	stress-strain	curves.	Formulations	were	
tested	at	32	°C	and	100	µm/s	as	debonding	velocity.	(Black	line:	form.	no.	2,	grey	line:	form.	
no.	4,	light	grey	line:	form.	no.	6).	
 
 
In	order	to	understand	SEBS-made	PSAs	debonding	processes,	their	failure	mechanisms	
were	 studied	 and	 by	 the	 video	 streaming	 two	 typical	 debonding	 mechanisms	 were	
identified.		
Form.	nos.	1-6	showed	a	liquid-like	behavior	at	the	lower	debonding	velocity	with	many	
digitations,	because	they	have	more	time	to	relax	and	reorganize	(Fig.	3.3,	black	line).		
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Figure	3.3	–	Typical	stress-strain	curves,	schematic	and	video	captures	
of	the	debonding	mechanisms	at	10	µm/s	(black	line)	and	1000	µm/s	(grey	line)	and	32	°C	of	
the	formulation	no.	5.	
 
 
On	the	contrary,	at	the	faster	debonding	velocity,	they	did	not	have	time	to	relax.	 In	
these	conditions,	PSAs	showed	a	more	solid-like	behavior	and	the	formation	of	a	high	
number	of	cavities	was	observed	(Fig.	3.3,	gray	line).		
Considering	that	in	the	normal	usage	conditions	a	patch	must	adhere	to	the	skin	for	a	
long	 time,	 the	 studied	 PSAs	will	 have	 time	 for	 relaxation,	 showing	 in	 the	debonding	
phase	an	interfacial	behavior.	This	latter	mechanism	is	required	in	order	to	achieve	an	
adhesive	failure	without	residues	of	adhesive	after	the	debonding	process.		
The	adhesive	behavior	during	the	debonding	phase	as	well	as	the	shape	of	the	stress-
strain	curve	and	the	debonding	mechanisms	did	not	qualitatively	change	neither	with	
polymer	nor	tackifier	molecular	weight	at	all	the	tested	debonding	rates.		
As	far	as	the	influence	of	the	debonding	velocity	on	the	main	adhesive	parameters	is	
concerned,	the	maximum	nominal	stress	and	the	work	of	adhesion	increased	increasing	
the	debonding	velocity,	at	least	up	to	the	value	taken	into	consideration.	This	behavior	
can	be	attributed	to	the	viscoelastic	losses	occurring	in	the	adhesive	layer	which	should	
increase	with	increasing	deformation	rate.		
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3.3.2	Placebo	patches	characterization	
The	thickness	of	both	placebo	and	drug-loaded	matrices	was	in	the	49	-	55	µm	range.	
Considering	the	accuracy	of	the	instrument,	all	the	matrices	can	be	considered	similar.		
The	shear	adhesion	represents	the	ability	of	the	matrix	to	flow	and	measures	the	ability	
of	a	PSA	to	adhere	to	a	standard	steel	panel	under	constant	stress	[17].	Conversely	to	
the	results	obtained	in	the	rheological	studies,	the	increase	of	the	molecular	weight	of	
SEBS	determined	a	reduction	of	the	shear	adhesion	values	(Tab.	3.3).	
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Table	3.3	–	Adhesive	properties	of	placebo	patches:	shear	adhesion,	
peel	adhesion	and	tack	(ball	no.)	evaluated	by	inclined	rolling	ball	test.	
Form.	
code	
Shear	adhesion	
(min)	
Peel	adhesion	
(cN/cm)	
Ball	No.	
1	 21.2	±	3.5	 37.8	±	9.3	 5	
2	 23.2	±	1.0	 38.0	±	9.0	 5	
3	 9.4	±	0.7	 26.4	±	2.6	 8	
4	 10.2	±	2.3	 25.8	±	3.3	 8	
5	 2.4	±	0.2	 48.0	±	9.7	 12	
6	 3.6	±	0.2	 48.6	±	10.3	 12	
 
 
This	 unexpected	 pattern	 can	 be	 explained	 considering	 that	 the	 patches	 detached	
adhesively	(i.e.	the	adherent	plate	was	clean	after	the	detachment);	as	a	consequence,	
the	shear	adhesion	results	can	not	be	considered	as	a	true	measure	of	the	PSAs	internal	
strength	 [17].	 The	 good	 cohesive	 properties	 of	 the	 prepared	 adhesive	 matrices	 are	
further	supported	by	the	lack	of	cold	flow	after	storage	at	40	°C	over	1	month	that	was	
in	agreement	with	the	rheological	characterization,	in	which	the	placebo	PSA	presented	
more	elastic	than	viscous	character.	Indeed,	it	was	demonstrated	in	a	previous	work	that	
patches	present	cold	flow	when	the	polymeric	matrix	shows	a	more	viscous	character	
[12].	Moving	the	attention	toward	the	tackifiers,	an	influence	of	their	molecular	weight	
can	be	noted	even	if	this	effect	resulted	statistically	significant	only	in	the	formulations	
made	with	SEBS-H	(p	<	0.05).	In	particular,	the	higher	the	molecular	weight	of	the	resin,	
the	higher	the	shear	adhesion	values.	
The	peel	adhesion	represents	the	force	required	to	peel	away	a	patch	from	a	substrate	
[17].	 The	 low	peel	 values	 (Tab.	 3.3)	 could	be	 considered	 satisfactory,	 since	 it	 is	well	
known	that	high	values	could	hurt	and	cause	skin	damage	upon	removal.	Unfortunately,	
there	was	any	correlation	between	the	formulative	variables	and	patch	peel	strength.	
The	inclined	rolling	ball	test	provided	information	on	the	superficial	properties	of	the	
adhesive.	Indeed,	differences	in	the	diameter	of	the	balls	that	stop	on	the	adhesive	layer	
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were	evident	changing	SEBS-molecular	weight	(Tab.	3.2)	and	a	correlation	among	tack	
and	shear	adhesion	was	highlighted:	the	higher	the	number	of	ball,	the	lower	the	shear	
adhesion.  
 
 
3.3.3	Drug	loaded	patches	performances	
In	order	to	confirm	the	feasibility	to	design	transdermal	patches	made	of	SEBS,	patches	
loaded	with	IB	and	NT	were	prepared.	The	thickness	of	resulted	homogenous	being	in	
the	49	-	55	µm.	
The	 trend	shown	by	 the	placebo	patches	 in	 terms	of	 shear	 resistance	performances,	
namely	the	lower	the	SEBS	molecular	weight,	the	higher	the	shear	adhesion,	appeared	
evident	also	in	the	case	of	the	drug-loaded	patches.	
The	IB	and	NT	caused	a	general	reduction	in	shear	adhesion	values	suggesting	that	these	
small	molecules	could	act	as	plasticizer	(Tab.	3.4).		
The	 significant	 reduction	 (p	 <	 0.05)	 of	 the	 shear	 adhesion	 values	 correlated	 to	 the	
presence	 of	 both	 the	 selected	 drugs	 may	 be	 due	 to	 a	 reduction	 in	 the	 number	 of	
entanglements	 between	 the	 polymer	 chains,	 which	 determined	 an	 increase	 in	 the	
matrix	fluidity.	In	the	case	of	IB	such	a	reduction	of	shear	adhesion	values	resulted	much	
more	 evident	 when	 the	 EastotacÔ	 H100W	 was	 used,	 suggesting	 that	 in	 the	 softer	
matrices	also	the	Mw	of	aliphatic	tackifier	could	play	a	key	role	in	determining	the	shear	
adhesion	performances	of	the	patches.	The	addition	of	smaller	amount	of	the	cationic	
drug,	namely	the	NT,	determined	a	greater	reduction	of	the	shear	adhesion	values	with	
respect	to	the	10%	IB	(Tab.	3.4).		
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Table	3.4	-	Adhesive	properties	of	drug-loaded	patches:	shear	
adhesion,	peel	adhesion	and	tack	(ball	no.)	evaluated	by	inclined	
rolling	ball	test.	
Form.	
code	
Shear	adhesion	
(min)	
Peel	adhesion	
(cN/cm)	
Ball	No.	
7	 2.6	±	0.3	 75.8	±	9.6	 12	
8	 5.5	±	0.6	 76.0	±	11.7	 10	
9	 2.9	±	0.3	 42.3	±	2.9	 12	
10	 5.0	±	0.5	 45.0	±	3.8	 10	
11	 1.3	±	0.1	 36.4	±	10.0	 15	
12	 1.7	±	0.1	 37.0	±	10.1	 15	
13	 2.2	±	0.1	 37.9	±	1.9	 12	
 
 
The	softening	effect	of	the	IB	and	NT	on	the	SEBS	based	matrix	also	influenced	the	tack	
values	(Tab.	3.4).	Conversely,	the	peeling	of	the	patches	from	the	flat	surface	resulted	
unaffected	by	drug	loading.		
	
Drug	content	(Tab.	3.5)	satisfied	the	Ph.	Eur.	assay	for	the	uniformity	of	dosage	units.	
The	 IB	 or	NT	 release	was	 completed	within	 7	 hours	 and	 it	 followed	Higuchi	 pattern	
independently	of	the	SEBS	and	tackifier	molecular	weight.		
The	 IB	 release	 constants	 (Tab.	 3.5),	 calculated	 according	 to	 the	 Higuchi	 model,	
highlighted	as	 the	 IB	constant	 release	rate	was	significantly	 faster	by	using	SEBS-L	as	
polymer	 (p	 <	 0.05),	 but	 it	 was	 not	 dependent	 on	 the	 tackifier,	 suggesting	 that	 the	
softening	 effect,	 verified	 in	 the	 study	 of	 the	 adhesive	 properties	 of	 the	 drug	 loaded	
patches,	did	not	influence	the	drug	diffusivity.		
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Table	3.5	-	Drug	content	and	main	parameters	calculated	for	in	vitro	drug	release	and	in	vitro	
skin	permeation	experiments:	constant	drug	release	rate	(k),	steady	flux	(J)	and	cumulative	
drug	amount	permeated	at	the	end	of	the	experiment	(Q24h).	
Form.	
Code	
Drug	content	
(µg/cm2)	
k	
(h-0.5)	
J	
(µg/cm2	h)	
Q24h	
(µg/cm2)	
7	 674.4	±	22.8	 0.44	±	0.02	 21.94	±	0.48	 465.77	±	12.83	
8	 688.8	±	11.1	 0.43	±	0.02	 23.65	±	3.78	 522.80	±	107.73	
9	 773.1	±	12.4	 0.36	±	0.01	 15.44	±	2.59	 307.43	±	53.06	
10	 734.7	±	30.3	 0.36	±	0.03	 14.39	±	2.04	 304.32	±	44.68	
11	 573.1	±	17.5	 0.33	±	0.01	 13.03	±	3.30	 243.81	±	63.08	
12	 586.5	±	5.1	 0.31	±	0.01	 13.21	±	0.86	 241.84	±	15.45	
Ibupas®	 -*	 0.35	±	0.01	 11.79	±	4.62	 227.04	±	7.98	
13	 246.8	±	13.2	 0.61	±	0.06	 -*	 -*	
*:	not	determined.	
	
	
These	 data	 were	 in	 agreement	 with	 the	 rheological	 pattern:	 the	 higher	 the	 liquid	
character	of	 the	 formulation,	 the	 faster	 the	drug	 release	 rate.	Moreover,	 comparing	
these	data	with	 the	drug	 release	 results	obtained	by	dissolution	of	 the	commercially	
available	patch	loaded	with	IB,	namely	IbupasÒ,	the	drug	release	rate	from	form.	nos.	7,	
8	 and	 12	 resulted	 significantly	 different	 (p	<	 0.05).	 In	 particular,	 form.	 nos.	 7	 and	 8	
exhibited	faster	IB	release	rate	if	compared	to	that	of	IbupasÒ,	while	in	the	case	of	form.	
no.	12	it	resulted	slower.	
The	 release	constant	obtained	by	patches	 loaded	with	NT	confirmed	 its	capability	 to	
increase	 the	 fluidity	 of	 the	 matrix	 that	 was	 more	 effective	 if	 compared	 to	 IB.	 By	
comparing	k	values	of	formulations	nos.	8	and	13	was	confirmed	that	the	matrix	fluidity	
plays	 a	 key	 role	 in	 the	 drug	 release:	 the	 lower	 the	 viscosity	 of	 the	 PSA	 at	 a	 given	
temperature,	the	faster	the	release	rate.		
Aiming	 to	 deepen	 the	 information	 on	 the	 biopharmaceutical	 performances,	 in	 vitro	
permeation	studies	by	using	Franz	cell	and	pig	ear	skin	as	membrane	were	performed	
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on	 the	 patches	 loaded	 with	 IB	 (form.	 nos.	 7,	 8,	 9,	 10,	 11	 and	 12).	 Moreover,	 IB	
permeability	from	the	commercial	reference	product	(IbupasÒ)	was	also	evaluated.	
The	permeated	amount	after	24	hours	(Q24h)	through	the	pig	ear	skin	and	flux	(J)	of	IB	
from	the	formulated	patches	are	summarized	in	Table	3.5.	The	amount	of	IB	permeated	
was	 influenced	 by	 polymer	 molecular	 weight,	 but	 no	 by	 the	 tackifier	 (Fig.	 3.4):	 in	
particular,	the	lower	the	polymer	molecular	weight,	the	higher	the	IB	permeated.	
 
 
Figure	3.4	-	In	vitro	IB	permeation	profiles	through	ear-pig	skin	from	the	formulated	
transdermal	patches	and	from	the	commercial	reference	product	(IbupasÒ).	
 
 
Surprisingly,	the	IB	diffusion	through	the	skin	by	the	formulations	nos.	7	and	8	was	not	
limited	by	the	polymeric	matrix	if	compared	to	the	commercial	reference	product	(Fig.	
3.4).	These	data	correlated	with	obtained	results	regarding	drug	release	from	the	matrix.	
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3.4	Conclusions	
The	overall	data	suggested	that	SEBS	copolymers	is	a	suitable	material	to	prepare	drug	
in-adhesive	patches.	The	in	vitro	permeation	results	evidenced	that	SEBS	based	matrices	
are	suitable	to	administrate	drugs	with	different	chemical-physical	characteristics,	such	
as	 IB	 and	 NT.	 However,	 SEBS-low	 molecular	 weight	 is	 the	 polymer	 worthy	 of	
consideration	 to	 design	 transdermal	 patches	 because	 of	 its	 favorable	 viscoelastic	
behavior	 and	 its	 capability	 to	 not	 limit	 in	 vitro	 IB	 permeability	 if	 compared	 to	 the	
commercial	 reference	 product.	 The	 resin	 used	 to	 make	 the	 polymer	 sticky	 did	 not	
significantly	influence	the	rheological	behavior	and	adhesive	properties	placebo	SEBS-
matrices.	On	the	contrary,	concerning	the	drug	loaded	patches,	both	the	polymer	and	
resin	molecular	weight	and	the	 loaded	drug	affected	the	overall	 technological	and	 in	
vitro	biopharmaceutical	features	of	the	final	patch.	
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This	PhD	thesis	dealt	with	the	investigation	of	the	adhesive	and	mechanical	properties	
of	polymeric	matrices	in	order	to	design	transdermal	dosage	forms,	such	as	film-forming	
systems	and	transdermal	patches.	
The	overall	experimental	data	allowed	to	highlight	the	relevance	of	physicochemical	and	
technological	 as	 well	 as	 in	 vitro	 biopharmaceutical	 characterizations	 in	 defining	 the	
formulation	window	to	design	such	dosage	forms.	In	particular:	
(a)	 	by	studying	the	mechanical	properties	of	film-forming	systems	made	of	EuRL,	the	
importance	to	evaluate	the	outward	stickiness	and	elasticity	of	the	formed	film	was	
evidenced;		
(b)	 by	in	vitro	skin	permeation	studies	from	film-forming	systems	made	of	EuRL,	it	was	
highlighted	that	the	overall	absorption	process	can	be	significantly	influenced	not	
only	by	the	drug	thermodynamic	activity	in	the	film,	but	also	by	the	film	forming	
rate,	that	was	not	previously	considered	in	literature;		
(c)	 	by	evaluating	the	rheological	and	adhesive	properties	of	highly	plasticized	EuRL	for	
the	design	of	transdermal	patches,	the	relevance	of	the	viscoelasticity	extent	of	the	
polymeric	 matrices	 on	 the	 adhesive	 properties	 was	 evidenced,	 reflecting	 on	
debonding	pattern	and	shear	adhesion;	furthermore,	the	impact	of	the	viscoelastic	
properties	on	the	in	vitro	drug	release	was	highlighted;		
(d)	 by	 studying	 film-forming	 systems	 and	 transdermal	 patches	 made	 of	 EuRL,	 the	
versatility	 of	 this	 polymer,	 opportunely	 plasticized,	 in	 the	 design	 of	 both	 such	
dosage	forms	was	confirmed;		
(e)	 by	investigating	the	possibility	of	using	SEBS	for	the	design	of	patches,	the	impact	
of	rheological	behavior	on	both	adhesive	and	in	vitro	biopharmaceutical	properties	
was	confirmed	also	for	this	type	of	polymers.	
In	general,	the	characterization	of	the	final	dosage	form	in	terms	of	both	technological	
and	in	vitro	biopharmaceutical	performances	and	the	knowledge	of	the	main	features	
of	 the	polymeric	matrix,	namely	 rheological	behavior	and	mechanical	properties,	are	
crucial	 to	 identify	a	 formulative	window	for	designing	both	film-forming	systems	and	
transdermal	patches.	
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In	the	case	of	film-forming	systems	(Chapter	1),	the	evaluation	of	the	outward	stickiness	
resulted	important	to	define	an	initial	formulative	space	as	well	as	the	film	elasticity,	
that	plays	a	key	role	in	defining	a	whole	contact	between	the	pharmaceutical	dosage	
form	and	the	skin	independently	of	the	stresses	caused	by	body	movements.	The	in	vitro	
skin	 permeation	 studies	 of	 three	 model	 drugs,	 namely	 ibuprofen,	 ketoprofen	 and	
flurbiprofen,	 allowed	 to	 evidence	 that	 both	 the	 vehicle	 evaporation	 rate	 and	 the	
thermodynamic	 activity	 of	 the	 drug	 within	 the	 film	 influenced	 the	 extent	 of	 skin	
permeation.	In	particular,	the	evaporation	rate	of	the	vehicle,	that	depends	not	only	by	
the	volatile	 components,	but	also	by	 the	overall	 formulation	 composition	 (i.e.	 in	 the	
simplest	formula:	vehicle,	polymer,	plasticizer	and	drug),	affected	the	initial	partition	of	
the	drug	through	the	skin.	This	final	remark	is	due	to	the	formulation	metamorphosis,	
following	the	vehicle	evaporation,	which	can	lead	to	two	different	outcomes.	From	one	
side	an	increase	of	the	thermodynamic	activity	of	the	drug	within	the	final	formed	film	
can	occur,	promoting	the	permeation	through	the	skin.	On	the	other	side,	the	drug	can	
crystallize,	reducing	its	availability	for	the	partition	from	the	film	toward	the	skin	and,	
consequently,	compromising	the	whole	permeation	process.	
A	 series	of	 pressure-sensitive	 adhesives	made	of	 EuRL	 for	 the	design	of	 transdermal	
patches	were	formulated,	changing	the	solvent	used	to	solubilize	the	polymer	and	the	
type	and	content	of	plasticizer.	In	Chapter	2	the	effect	of	each	formulative	variable	on	
the	main	 rheological,	 adhesive	 and	 in	 vitro	 biopharmaceutical	 features	was	 studied.	
Interestingly,	 a	 relationship	 between	 the	 extent	 of	 viscoelasticity,	 the	 adhesive	
properties	and	drug	release	was	evidenced.	In	particular,	the	higher	the	liquid	character	
of	 the	adhesive	matrix,	 determined	 in	 terms	of	 relaxation	 time,	 the	 lower	 the	 shear	
resistance	and	the	higher	the	in	vitro	drug	release	rate.	Moreover,	even	in	the	case	of	
these	patches,	as	well	as	in	the	case	of	film	forming	systems,	the	effect	of	the	loaded	
drugs,	namely	ibuprofen,	ketoprofen	and	flurbiprofen,	on	the	main	pressure-sensitive	
adhesives	 characteristics	 cannot	 be	 overlooked.	 Indeed,	 a	 drug	 can	 behave	 like	 a	
plasticizer	or	an	antiplasticizer,	affecting	the	viscoelasticity	extent	of	the	final	patch	and,	
consequently,	the	other	correlated	features.	
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In	 the	 case	of	 SEBS	 (Chapter	3),	 the	 feasibility	 to	design	patches	was	demonstrated.	
Moreover,	the	effects	of	polymer	and	tackifier	molecular	weights	were	studied.	Even	if	
some	 formulations	 behaved	 as	 elastic	 materials,	 the	 relevance	 of	 studying	 the	
rheological	 behavior	 of	 a	 pressure-sensitive	 adhesive	 used	 to	 design	 a	 patch	 was	
verified.	As	a	matter	of	fact,	a	relationship	between	the	main	rheological	parameters,	
the	 adhesive	 properties	 and	 the	 in	 vitro	 biopharmaceutical	 performances	 was	
confirmed.	In	this	case,	the	higher	the	matrix	fluidity,	the	faster	the	in	vitro	drug	release	
and,	 consequently,	 the	higher	 the	 in	 vitro	 drug	permeated	amount	 through	 the	 skin	
within	24	hours.	Surprisingly,	patches	made	of	SEBS	allowed	to	 load	a	high	extent	of	
ibuprofen,	without	its	crystallization,	and	to	obtain	a	permeated	amount	of	such	drug	
after	24	hours	of	application	higher	if	compared	to	the	commercial	available	patch	made	
of	an	acrylate	copolymer.	
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